

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 November 2005 (03.11.2005)

PCT

(10) International Publication Number
WO 2005/103709 A1

- (51) International Patent Classification⁷: **G01N 33/68**, C12Q 1/68, A61K 38/17
- (21) International Application Number:
PCT/EP2005/003824
- (22) International Filing Date: 12 April 2005 (12.04.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
04009781.8 24 April 2004 (24.04.2004) EP
- (71) Applicant (for all designated States except US): **BAYER HEALTHCARE AG** [DE/DE]; 51368 Leverkusen (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **GOLZ, Stefan** [DE/DE]; Bückmannsmühle 46, 45326 Essen (DE). **BRÜGGEMEIER, Ulf** [DE/DE]; Leysiefen 20, 42799 Leichlingen (DE). **GEERTS, Andreas** [DE/DE]; Schuckertstr. 29, 42113 Wuppertal (DE).
- (74) Common Representative: **BAYER HEALTHCARE AG**; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN G-PROTEIN COUPLED RECEPTOR FKSG79 (FKSG79)

(57) Abstract: The invention provides a human FKSG79 which is associated with the cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of FKSG79 as well as pharmaceutical compositions comprising such compounds.



WO 2005/103709 A1

Diagnostics and Therapeutics for Diseases Associated with Human G-Protein Coupled Receptor FKSG79 (FKSG79)

Technical field of the invention

5 The present invention is in the field of molecular biology, more particularly, the present invention relates to nucleic acid sequences and amino acid sequences of a human FKSG79 and its regulation for the treatment of cardiovascular diseases, infections, dermatological diseases, gastro-
enterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respira-
tory diseases, muscle skeleton diseases, neurological diseases and urological diseases in mammals.

Background of the invention

10 **G-Protein Coupled Receptors**

FKSG79 is a seven transmembrane G protein coupled receptor (GPCR) [[Mitaku et al. (2002)],
WO02061087, WO0198351, WO02068579]. Many medically significant biological processes are
mediated by signal transduction pathways that involve G-proteins [Lefkowitz, (1991)]. The family
of G-protein coupled receptors (GPCRs) includes receptors for hormones, neurotransmitters,
15 growth factors, and viruses. Specific examples of GPCRs include receptors for such diverse
agents as dopamine, calcitonine, adrenergic hormones, endotheline, cAMP, adenosine,
acetylcholine, serotonin, histamine, thrombin, kinine, follicle stimulating hormone, opsins,
endothelial differentiation gene-1, rhodopsins, odorants, cytomegalovirus, G-proteins themselves,
effector proteins such as phospholipase C, adenylyl cyclase, and phosphodiesterase, and actuator
20 proteins such as protein kinase A and protein kinase C.

GPCRs possess seven conserved membrane-spanning domains connecting at least eight divergent
hydrophilic loops. GPCRs, also known as seven transmembrane, 7TM, receptors, have been
characterized as including these seven conserved hydrophobic stretches of about 20 to 30 amino
acids, connecting at least eight divergent hydrophilic loops. Most GPCRs have single conserved
25 cysteine residues in each of the first two extracellular loops, which form disulfide bonds that are
believed to stabilize functional protein structure. The seven transmembrane regions are designated
as TM1, TM2, TM3, TM4, TM5, TM6, and TM7. TM3 is being implicated with signal
transduction. Phosphorylation and lipidation (palmitoylation or farnesylation) of cysteine residues
can influence signal transduction of some GPCRs. Most GPCRs contain potential phosphorylation
30 sites within the third cytoplasmic loop and/or the carboxy terminus. For several GPCRs, such as
the beta-adrenergic receptor, phosphorylation by protein kinase A and/or specific receptor kinases
mediates receptor desensitization.

For some receptors, the ligand binding sites of GPCRs are believed to comprise hydrophilic sockets formed by several GPCR transmembrane domains. The hydrophilic sockets are surrounded by hydrophobic residues of the GPCRs. The hydrophilic side of each GPCR transmembrane helix is postulated to face inward and form a polar ligand binding site. TM3 is being implicated with several GPCRs as having a ligand binding site, such as the TM3 aspartate residue. TM5 serines, a TM6 asparagine, and TM6 or TM7 phenylalanines or tyrosines also are implicated in ligand binding.

GPCRs are coupled inside the cell by heterotrimeric G-proteins to various intracellular enzymes, ion channels, and transporters. Different G-protein alpha-subunits preferentially stimulate particular effectors to modulate various biological functions in a cell. Phosphorylation of cytoplasmic residues of GPCRs is an important mechanism for the regulation of some GPCRs. For example, in one form of signal transduction, the effect of hormone binding is the activation of the enzyme, adenylate cyclase, inside the cell. Enzyme activation by hormones is dependent on the presence of the nucleotide GTP. GTP also influences hormone binding. A G-protein connects the hormone receptor to adenylate cyclase. G-protein exchanges GTP for bound GDP when activated by a hormone receptor. The GTP-carrying form then binds to activated adenylate cyclase. Hydrolysis of GTP to GDP, catalyzed by the G-protein itself, returns the G-protein to its basal, inactive form. Thus, the G-protein serves a dual role, as an intermediate that relays the signal from receptor to effector, and as a clock that controls the duration of the signal.

Over the past 15 years, nearly 350 therapeutic agents targeting 7TM receptors have been successfully introduced into the market. This indicates that these receptors have an established, proven history as therapeutic targets. Clearly, there is a need for identification and characterization of further receptors which can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, cancers, allergies including asthma, cardiovascular diseases including acute heart failure, hypotension, hypertension, angina pectoris, myocardial infarction, hematological diseases, genito-urinary diseases including urinary incontinence and benign prostate hyperplasia, osteoporosis, peripheral and central nervous system disorders including pain, Alzheimer's disease and Parkinson's disease, respiratory diseases, metabolic diseases, inflammatory diseases, gastro-enterological diseases, diseases of the endocrine system, dermatological diseases, diseases of muscles or the skeleton, immunological diseases, developmental diseases or diseases of the reproductive system.

TaqMan-Technology / expression profiling

TaqMan is a recently developed technique, in which the release of a fluorescent reporter dye from a hybridisation probe in real-time during a polymerase chain reaction (PCR) is proportional to the accumulation of the PCR product. Quantification is based on the early, linear part of the reaction, and by determining the threshold cycle (CT), at which fluorescence above background is first detected.

Gene expression technologies may be useful in several areas of drug discovery and development, such as target identification, lead optimization, and identification of mechanisms of action. The TaqMan technology can be used to compare differences between expression profiles of normal tissue and diseased tissue. Expression profiling has been used in identifying genes, which are up- or downregulated in a variety of diseases. An interesting application of expression profiling is temporal monitoring of changes in gene expression during disease progression and drug treatment or in patients versus healthy individuals. The premise in this approach is that changes in pattern of gene expression in response to physiological or environmental stimuli (e.g., drugs) may serve as indirect clues about disease-causing genes or drug targets. Moreover, the effects of drugs with established efficacy on global gene expression patterns may provide a guidepost, or a genetic signature, against which a new drug candidate can be compared.

FKSG79

The nucleotide sequence of FKSG79 is accessible in the databases by the accession number NM_032553 and is given in SEQ ID NO:1. The amino acid sequence of FKSG79 depicted in SEQ ID NO:2.

G protein-coupled receptors (GPCRs) are integral membrane proteins containing 7 putative transmembrane domains (TMs). These proteins mediate signals to the interior of the cell via activation of heterotrimeric G proteins that in turn activate various effector proteins, ultimately resulting in a physiologic response.

Mitaku et al. [Mitaku et al. (2002)] discovered the sequence of a novel human GPCR, which they called FSKG79. The receptor could be a member of the purinergic receptor family.

FKSG79 is published in patents WO02061087, WO0198351 and WO02068579.

Summary of the invention

The invention relates to novel disease associations of FKSG79 polypeptides and polynucleotides. The invention also relates to novel methods of screening for therapeutic agents for the treatment of

cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal. The invention also relates to pharmaceutical compositions for the treatment of cardiovascular diseases, infections, 5 dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising a FKSG79 polypeptide, a FKSG79 polynucleotide, or regulators of FKSG79 or modulators of FKSG79 activity. The invention further comprises methods of diagnosing cardiovascular diseases, infections, dermatological diseases, 10 gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal.

Brief Description of the Drawings

Fig. 1 shows the nucleotide sequence of a FKSG79 receptor polynucleotide (SEQ ID NO:1).

15 Fig. 2 shows the amino acid sequence of a FKSG79 receptor polypeptide (SEQ ID NO:2).

Fig. 3 shows the nucleotide sequence of a primer useful for the invention (SEQ ID NO:3).

Fig. 4 shows the nucleotide sequence of a primer useful for the invention (SEQ ID NO:4).

Fig. 5 shows a nucleotide sequence useful as a probe to detect proteins of the invention (SEQ ID NO:5).

Detailed description of the invention

Definition of terms

An "oligonucleotide" is a stretch of nucleotide residues which has a sufficient number of bases to be used as an oligomer, amplimer or probe in a polymerase chain reaction (PCR). Oligonucleotides are prepared from genomic or cDNA sequence and are used to amplify, reveal, or 25 confirm the presence of a similar DNA or RNA in a particular cell or tissue. Oligonucleotides or oligomers comprise portions of a DNA sequence having at least about 10 nucleotides and as many as about 35 nucleotides, preferably about 25 nucleotides.

"Probes" may be derived from naturally occurring or recombinant single- or double-stranded nucleic acids or may be chemically synthesized. They are useful in detecting the presence of 30 identical or similar sequences. Such probes may be labeled with reporter molecules using nick

translation, Klenow fill-in reaction, PCR or other methods well known in the art. Nucleic acid probes may be used in southern, northern or in situ hybridizations to determine whether DNA or RNA encoding a certain protein is present in a cell type, tissue, or organ.

5 A "fragment of a polynucleotide" is a nucleic acid that comprises all or any part of a given nucleotide molecule, the fragment having fewer nucleotides than about 6 kb, preferably fewer than about 1 kb.

"Reporter molecules" are radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents which associate with a particular nucleotide or amino acid sequence, thereby establishing the presence of a certain sequence, or allowing for the quantification of a certain sequence.

10 "Chimeric" molecules may be constructed by introducing all or part of the nucleotide sequence of this invention into a vector containing additional nucleic acid sequence which might be expected to change any one or several of the following FKSG79 characteristics: cellular location, distribution, ligand-binding affinities, interchain affinities, degradation/turnover rate, signaling, etc.

15 "Active", with respect to a FKSG79 polypeptide, refers to those forms, fragments, or domains of a FKSG79 polypeptide which retain the biological and/or antigenic activity of a FKSG79 polypeptide.

20 "Naturally occurring FKSG79 polypeptide" refers to a polypeptide produced by cells which have not been genetically engineered and specifically contemplates various polypeptides arising from post-translational modifications of the polypeptide including but not limited to acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.

"Derivative" refers to polypeptides which have been chemically modified by techniques such as ubiquitination, labeling (see above), pegylation (derivatization with polyethylene glycol), and chemical insertion or substitution of amino acids such as ornithine which do not normally occur in human proteins.

25 "Conservative amino acid substitutions" result from replacing one amino acid with another having similar structural and/or chemical properties, such as the replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.

30 "Insertions" or "deletions" are typically in the range of about 1 to 5 amino acids. The variation allowed may be experimentally determined by producing the peptide synthetically while systematically making insertions, deletions, or substitutions of nucleotides in the sequence using recombinant DNA techniques.

A "signal sequence" or "leader sequence" can be used, when desired, to direct the polypeptide through a membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous sources by recombinant DNA techniques.

5 An "oligopeptide" is a short stretch of amino acid residues and may be expressed from an oligonucleotide. Oligopeptides comprise a stretch of amino acid residues of at least 3, 5, 10 amino acids and at most 10, 15, 25 amino acids, typically of at least 9 to 13 amino acids, and of sufficient length to display biological and/or antigenic activity.

10 "Inhibitor" is any substance which retards or prevents a chemical or physiological reaction or response. Common inhibitors include but are not limited to antisense molecules, antibodies, and antagonists.

"Standard expression" is a quantitative or qualitative measurement for comparison. It is based on a statistically appropriate number of normal samples and is created to use as a basis of comparison when performing diagnostic assays, running clinical trials, or following patient treatment profiles.

15 "Animal" as used herein may be defined to include human, domestic (e.g., cats, dogs, etc.), agricultural (e.g., cows, horses, sheep, etc.) or test species (e.g., mouse, rat, rabbit, etc.).

A "FKSG79 polynucleotide", within the meaning of the invention, shall be understood as being a nucleic acid molecule selected from a group consisting of

- (i) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2,
- 20 (ii) nucleic acid molecules comprising the sequence of SEQ ID NO: 1,
- (iii) nucleic acid molecules having the sequence of SEQ ID NO: 1,
- (iv) nucleic acid molecules the complementary strand of which hybridizes under stringent conditions to a nucleic acid molecule of (i), (ii), or (iii); and
- (v) nucleic acid molecules the sequence of which differs from the sequence of a nucleic acid
25 molecule of (iii) due to the degeneracy of the genetic code;

wherein the polypeptide encoded by said nucleic acid molecule has FKSG79 activity.

A "FKSG79 polypeptide", within the meaning of the invention, shall be understood as being a polypeptide selected from a group consisting of

- (i) polypeptides having the sequence of SEQ ID NO: 2,
- (ii) polypeptides comprising the sequence of SEQ ID NO: 2,
- (iii) polypeptides encoded by FKSG79 polynucleotides; and
- (iv) polypeptides which show at least 99%, 98%, 95%, 90%, or 80% homology with a polypeptide of (i), (ii), or (iii);

wherein said polypeptide has FKSG79 activity.

The nucleotide sequences encoding a FKSG79 (or their complement) have numerous applications in techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use in the construction of oligomers for PCR, use for chromosome and gene mapping, use in the recombinant production of FKSG79, and use in generation of antisense DNA or RNA, their chemical analogs and the like. Uses of nucleotides encoding a FKSG79 disclosed herein are exemplary of known techniques and are not intended to limit their use in any technique known to a person of ordinary skill in the art. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, e.g., the triplet genetic code, specific base pair interactions, etc.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of FKSG79 - encoding nucleotide sequences may be produced. Some of these will only bear minimal homology to the nucleotide sequence of the known and naturally occurring FKSG79. The invention has specifically contemplated each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring FKSG79, and all such variations are to be considered as being specifically disclosed.

Although the nucleotide sequences which encode a FKSG79, its derivatives or its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring FKSG79 polynucleotide under stringent conditions, it may be advantageous to produce nucleotide sequences encoding FKSG79 polypeptides or its derivatives possessing a substantially different codon usage. Codons can be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding a FKSG79 polypeptide and/or its derivatives without altering the

encoded amino acid sequence include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

5 Nucleotide sequences encoding a FKSG79 polypeptide may be joined to a variety of other nucleotide sequences by means of well established recombinant DNA techniques. Useful nucleotide sequences for joining to FKSG79 polynucleotides include an assortment of cloning vectors such as plasmids, cosmids, lambda phage derivatives, phagemids, and the like. Vectors of interest include expression vectors, replication vectors, probe generation vectors, sequencing vectors, etc. In general, vectors of interest may contain an origin of replication functional in at least one organism, convenient restriction endonuclease sensitive sites, and selectable markers for one or more host cell systems.

10 Another aspect of the subject invention is to provide for FKSG79-specific hybridization probes capable of hybridizing with naturally occurring nucleotide sequences encoding FKSG79. Such probes may also be used for the detection of similar GPCR encoding sequences and should preferably show at least 40% nucleotide identity to FKSG79 polynucleotides. The hybridization probes of the subject invention may be derived from the nucleotide sequence presented as SEQ ID NO: 1 or from genomic sequences including promoter, enhancers or introns of the native gene. Hybridization probes may be labelled by a variety of reporter molecules using techniques well known in the art.

20 It will be recognized that many deletional or mutational analogs of FKSG79 polynucleotides will be effective hybridization probes for FKSG79 polynucleotides. Accordingly, the invention relates to nucleic acid sequences that hybridize with such FKSG79 encoding nucleic acid sequences under stringent conditions.

25 "Stringent conditions" refers to conditions that allow for the hybridization of substantially related nucleic acid sequences. For instance, such conditions will generally allow hybridization of sequence with at least about 85% sequence identity, preferably with at least about 90% sequence identity, more preferably with at least about 95% sequence identity. Hybridization conditions and probes can be adjusted in well-characterized ways to achieve selective hybridization of human-derived probes. Stringent conditions, within the meaning of the invention are 65°C in a buffer containing 1 mM EDTA, 0.5 M NaHPO₄ (pH 7.2), 7 % (w/v) SDS.

30 Nucleic acid molecules that will hybridize to FKSG79 polynucleotides under stringent conditions can be identified functionally. Without limitation, examples of the uses for hybridization probes include: histochemical uses such as identifying tissues that express FKSG79; measuring mRNA

levels, for instance to identify a sample's tissue type or to identify cells that express abnormal levels of FKSG79; and detecting polymorphisms of FKSG79.

5 PCR provides additional uses for oligonucleotides based upon the nucleotide sequence which encodes FKSG79. Such probes used in PCR may be of recombinant origin, chemically synthesized, or a mixture of both. Oligomers may comprise discrete nucleotide sequences employed under optimized conditions for identification of FKSG79 in specific tissues or diagnostic use. The same two oligomers, a nested set of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for identification of closely related DNAs or RNAs.

10 Rules for designing polymerase chain reaction (PCR) primers are now established, as reviewed by PCR Protocols. Degenerate primers, i.e., preparations of primers that are heterogeneous at given sequence locations, can be designed to amplify nucleic acid sequences that are highly homologous to, but not identical with FKSG79. Strategies are now available that allow for only one of the primers to be required to specifically hybridize with a known sequence. For example, appropriate
15 nucleic acid primers can be ligated to the nucleic acid sought to be amplified to provide the hybridization partner for one of the primers. In this way, only one of the primers need be based on the sequence of the nucleic acid sought to be amplified.

PCR methods for amplifying nucleic acid will utilize at least two primers. One of these primers will be capable of hybridizing to a first strand of the nucleic acid to be amplified and of priming
20 enzyme-driven nucleic acid synthesis in a first direction. The other will be capable of hybridizing the reciprocal sequence of the first strand (if the sequence to be amplified is single stranded, this sequence will initially be hypothetical, but will be synthesized in the first amplification cycle) and of priming nucleic acid synthesis from that strand in the direction opposite the first direction and towards the site of hybridization for the first primer. Conditions for conducting such
25 amplifications, particularly under preferred stringent hybridization conditions, are well known.

Other means of producing specific hybridization probes for FKSG79 include the cloning of nucleic acid sequences encoding FKSG79 or FKSG79 derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerase as T7
30 or SP6 RNA polymerase and the appropriate reporter molecules.

It is possible to produce a DNA sequence, or portions thereof, entirely by synthetic chemistry. After synthesis, the nucleic acid sequence can be inserted into any of the many available DNA vectors and their respective host cells using techniques which are well known in the art.

Moreover, synthetic chemistry may be used to introduce mutations into the nucleotide sequence. Alternately, a portion of sequence in which a mutation is desired can be synthesized and recombined with longer portion of an existing genomic or recombinant sequence.

FKSG79 polynucleotides may be used to produce a purified oligo-or polypeptide using well known methods of recombinant DNA technology. The oligopeptide may be expressed in a variety of host cells, either prokaryotic or eukaryotic. Host cells may be from the same species from which the nucleotide sequence was derived or from a different species. Advantages of producing an oligonucleotide by recombinant DNA technology include obtaining adequate amounts of the protein for purification and the availability of simplified purification procedures.

10 **Quantitative determinations of nucleic acids**

An important step in the molecular genetic analysis of human disease is often the enumeration of the copy number of a nucleic acid or the relative expression of a gene in particular tissues.

Several different approaches are currently available to make quantitative determinations of nucleic acids. Chromosome-based techniques, such as comparative genomic hybridization (CGH) and fluorescent in situ hybridization (FISH) facilitate efforts to cytogenetically localize genomic regions that are altered in tumor cells. Regions of genomic alteration can be narrowed further using loss of heterozygosity analysis (LOH), in which disease DNA is analyzed and compared with normal DNA for the loss of a heterozygous polymorphic marker. The first experiments used restriction fragment length polymorphisms (RFLPs) [Johnson, (1989)], or hypervariable minisatellite DNA [Barnes, 2000]. In recent years LOH has been performed primarily using PCR amplification of microsatellite markers and electrophoresis of the radio labelled [Jeffreys, (1985)] or fluorescently labelled PCR products [Weber, (1990)] and compared between paired normal and disease DNAs.

A number of other methods have also been developed to quantify nucleic acids [Gergen, (1992)]. More recently, PCR and RT-PCR methods have been developed which are capable of measuring the amount of a nucleic acid in a sample. One approach, for example, measures PCR product quantity in the log phase of the reaction before the formation of reaction products plateaus [Thomas, (1980)].

A gene sequence contained in all samples at relatively constant quantity is typically utilized for sample amplification efficiency normalization. This approach, however, suffers from several drawbacks. The method requires that each sample has equal input amounts of the nucleic acid and that the amplification efficiency between samples is identical until the time of analysis.

Furthermore, it is difficult using the conventional methods of PCR quantitation such as gel electrophoresis or plate capture hybridization to determine that all samples are in fact analyzed during the log phase of the reaction as required by the method.

Another method called quantitative competitive (QC)-PCR, as the name implies, relies on the inclusion of an internal control competitor in each reaction [Piatak, (1993), BioTechniques]. The efficiency of each reaction is normalized to the internal competitor. A known amount of internal competitor is typically added to each sample. The unknown target PCR product is compared with the known competitor PCR product to obtain relative quantitation. A difficulty with this general approach lies in developing an internal control that amplifies with the same efficiency than the target molecule.

5' Fluorogenic Nuclease Assays

Fluorogenic nuclease assays are a real time quantitation method that uses a probe to monitor formation of amplification product. The basis for this method of monitoring the formation of amplification product is to measure continuously PCR product accumulation using a dual-labelled fluorogenic oligonucleotide probe, an approach frequently referred to in the literature simply as the "TaqMan method" [Piatak,(1993), Science; Heid, (1996); Gibson, (1996); Holland. (1991)].

The probe used in such assays is typically a short (about 20-25 bases) oligonucleotide that is labeled with two different fluorescent dyes. The 5' terminus of the probe is attached to a reporter dye and the 3' terminus is attached to a quenching dye, although the dyes could be attached at other locations on the probe as well. The probe is designed to have at least substantial sequence complementarity with the probe binding site. Upstream and downstream PCR primers which bind to flanking regions of the locus are added to the reaction mixture. When the probe is intact, energy transfer between the two fluorophors occurs and the quencher quenches emission from the reporter. During the extension phase of PCR, the probe is cleaved by the 5' nuclease activity of a nucleic acid polymerase such as Taq polymerase, thereby releasing the reporter from the oligonucleotide-quencher and resulting in an increase of reporter emission intensity which can be measured by an appropriate detector.

One detector which is specifically adapted for measuring fluorescence emissions such as those created during a fluorogenic assay is the ABI 7700 or 4700 HT manufactured by Applied Biosystems, Inc. in Foster City, Calif. The ABI 7700 uses fiber optics connected with each well in a 96-or 384 well PCR tube arrangement. The instrument includes a laser for exciting the labels and is capable of measuring the fluorescence spectra intensity from each tube with continuous monitoring during PCR amplification. Each tube is re-examined every 8.5 seconds.

Computer software provided with the instrument is capable of recording the fluorescence intensity of reporter and quencher over the course of the amplification. The recorded values will then be used to calculate the increase in normalized reporter emission intensity on a continuous basis. The increase in emission intensity is plotted versus time, i.e., the number of amplification cycles, to produce a continuous measure of amplification. To quantify the locus in each amplification reaction, the amplification plot is examined at a point during the log phase of product accumulation. This is accomplished by assigning a fluorescence threshold intensity above background and determining the point at which each amplification plot crosses the threshold (defined as the threshold cycle number or Ct). Differences in threshold cycle number are used to quantify the relative amount of PCR target contained within each tube. Assuming that each reaction functions at 100% PCR efficiency, a difference of one Ct represents a two-fold difference in the amount of starting template. The fluorescence value can be used in conjunction with a standard curve to determine the amount of amplification product present.

Non-Probe-Based Detection Methods

A variety of options are available for measuring the amplification products as they are formed. One method utilizes labels, such as dyes, which only bind to double stranded DNA. In this type of approach, amplification product (which is double stranded) binds dye molecules in solution to form a complex. With the appropriate dyes, it is possible to distinguish between dye molecules free in solution and dye molecules bound to amplification product. For example, certain dyes fluoresce only when bound to amplification product. Examples of dyes which can be used in methods of this general type include, but are not limited to, Syber Green.TM. and Pico Green from Molecular Probes, Inc. of Eugene, Oreg., ethidium bromide, propidium iodide, chromomycin, acridine orange, Hoechst 33258, Toto-1, Yoyo-1, DAPI (4',6-diamidino-2-phenylindole hydrochloride).

Another real time detection technique measures alteration in energy fluorescence energy transfer between fluorophors conjugated with PCR primers [Livak, (1995)].

Probe-Based Detection Methods

These detection methods involve some alteration to the structure or conformation of a probe hybridized to the locus between the amplification primer pair. In some instances, the alteration is caused by the template-dependent extension catalyzed by a nucleic acid polymerase during the amplification process. The alteration generates a detectable signal which is an indirect measure of the amount of amplification product formed.

For example, some methods involve the degradation or digestion of the probe during the extension reaction. These methods are a consequence of the 5'-3' nuclease activity associated with some nucleic acid polymerases. Polymerases having this activity cleave mononucleotides or small oligonucleotides from an oligonucleotide probe annealed to its complementary sequence located within the locus.

The 3' end of the upstream primer provides the initial binding site for the nucleic acid polymerase. As the polymerase catalyzes extension of the upstream primer and encounters the bound probe, the nucleic acid polymerase displaces a portion of the 5' end of the probe and through its nuclease activity cleaves mononucleotides or oligonucleotides from the probe.

The upstream primer and the probe can be designed such that they anneal to the complementary strand in close proximity to one another. In fact, the 3' end of the upstream primer and the 5' end of the probe may abut one another. In this situation, extension of the upstream primer is not necessary in order for the nucleic acid polymerase to begin cleaving the probe. In the case in which intervening nucleotides separate the upstream primer and the probe, extension of the primer is necessary before the nucleic acid polymerase encounters the 5' end of the probe. Once contact occurs and polymerization continues, the 5'-3' exonuclease activity of the nucleic acid polymerase begins cleaving mononucleotides or oligonucleotides from the 5' end of the probe. Digestion of the probe continues until the remaining portion of the probe dissociates from the complementary strand.

In solution, the two end sections can hybridize with each other to form a hairpin loop. In this conformation, the reporter and quencher dye are in sufficiently close proximity that fluorescence from the reporter dye is effectively quenched by the quencher dye. Hybridized probe, in contrast, results in a linearized conformation in which the extent of quenching is decreased. Thus, by monitoring emission changes for the two dyes, it is possible to indirectly monitor the formation of amplification product.

Probes

The labeled probe is selected so that its sequence is substantially complementary to a segment of the test locus or a reference locus. As indicated above, the nucleic acid site to which the probe binds should be located between the primer binding sites for the upstream and downstream amplification primers.

Primers

The primers used in the amplification are selected so as to be capable of hybridizing to sequences at flanking regions of the locus being amplified. The primers are chosen to have at least substantial complementarity with the different strands of the nucleic acid being amplified. When a probe is utilized to detect the formation of amplification products, the primers are selected in such that they flank the probe, i.e. are located upstream and downstream of the probe.

The primer must have sufficient length so that it is capable of priming the synthesis of extension products in the presence of an agent for polymerization. The length and composition of the primer depends on many parameters, including, for example, the temperature at which the annealing reaction is conducted, proximity of the probe binding site to that of the primer, relative concentrations of the primer and probe and the particular nucleic acid composition of the probe. Typically the primer includes 15-30 nucleotides. However, the length of the primer may be more or less depending on the complexity of the primer binding site and the factors listed above.

Labels for Probes and Primers

The labels used for labeling the probes or primers of the current invention and which can provide the signal corresponding to the quantity of amplification product can take a variety of forms. As indicated above with regard to the 5' fluorogenic nuclease method, a fluorescent signal is one signal which can be measured. However, measurements may also be made, for example, by monitoring radioactivity, colorimetry, absorption, magnetic parameters, or enzymatic activity. Thus, labels which can be employed include, but are not limited to, fluorophores, chromophores, radioactive isotopes, electron dense reagents, enzymes, and ligands having specific binding partners (e.g., biotin-avidin).

Monitoring changes in fluorescence is a particularly useful way to monitor the accumulation of amplification products. A number of labels useful for attachment to probes or primers are commercially available including fluorescein and various fluorescein derivatives such as FAM, HEX, TET and JOE (all which are available from Applied Biosystems, Foster City, Calif.); lucifer yellow, and coumarin derivatives.

Labels may be attached to the probe or primer using a variety of techniques and can be attached at the 5' end, and/or the 3' end and/or at an internal nucleotide. The label can also be attached to spacer arms of various sizes which are attached to the probe or primer. These spacer arms are useful for obtaining a desired distance between multiple labels attached to the probe or primer.

In some instances, a single label may be utilized; whereas, in other instances, such as with the 5' fluorogenic nuclease assays for example, two or more labels are attached to the probe. In cases wherein the probe includes multiple labels, it is generally advisable to maintain spacing between the labels which is sufficient to permit separation of the labels during digestion of the probe through the 5'-3' nuclease activity of the nucleic acid polymerase.

Patients Exhibiting Symptoms of Disease

A number of diseases are associated with changes in the copy number of a certain gene. For patients having symptoms of a disease, the real-time PCR method can be used to determine if the patient has copy number alterations which are known to be linked with diseases that are associated with the symptoms the patient has.

FKSG79 expression

FKSG79 fusion proteins

Fusion proteins are useful for generating antibodies against FKSG79 polypeptides and for use in various assay systems. For example, fusion proteins can be used to identify proteins which interact with portions of FKSG79 polypeptides. Protein affinity chromatography or library-based assays for protein-protein interactions, such as the yeast two-hybrid or phage display systems, can be used for this purpose. Such methods are well known in the art and also can be used as drug screens.

A FKSG79 fusion protein comprises two polypeptide segments fused together by means of a peptide bond. The first polypeptide segment can comprise at least 54, 75, 100, 125, 139, 150, 175, 200, 225, 250, or 275 contiguous amino acids of SEQ ID NO: 2 or of a biologically active variant, such as those described above. The first polypeptide segment also can comprise full-length FKSG79.

The second polypeptide segment can be a full-length protein or a protein fragment. Proteins commonly used in fusion protein construction include, but are not limited to β galactosidase, β -glucuronidase, green fluorescent protein (GFP), autofluorescent proteins, including blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horseradish peroxidase (HRP), and chloramphenicol acetyltransferase (CAT). Additionally, epitope tags are used in fusion protein constructions, including histidine (His) tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Other fusion constructions can include maltose binding protein (MBP), S-tag, Lex a DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, herpes simplex virus (HSV) BP16 protein fusions and G-protein

fusions (for example G(alpha)16, Gs, Gi). A fusion protein also can be engineered to contain a cleavage site located adjacent to the FKSG79.

Preparation of Polynucleotides

5 A naturally occurring FKSG79 polynucleotide can be isolated free of other cellular components such as membrane components, proteins, and lipids. Polynucleotides can be made by a cell and isolated using standard nucleic acid purification techniques, or synthesized using an amplification technique, such as the polymerase chain reaction (PCR), or by using an automatic synthesizer. Methods for isolating polynucleotides are routine and are known in the art. Any such technique for obtaining a polynucleotide can be used to obtain isolated FKSG79 polynucleotides. For
0 example, restriction enzymes and probes can be used to isolate polynucleotide fragments which comprise FKSG79 nucleotide sequences. Isolated polynucleotides are in preparations which are free or at least 70, 80, or 90% free of other molecules.

FKSG79 cDNA molecules can be made with standard molecular biology techniques, using FKSG79 mRNA as a template. FKSG79 cDNA molecules can thereafter be replicated using
5 molecular biology techniques known in the art. An amplification technique, such as PCR, can be used to obtain additional copies of polynucleotides of the invention, using either human genomic DNA or cDNA as a template.

Alternatively, synthetic chemistry techniques can be used to synthesizes FKSG79 polynucleotides. The degeneracy of the genetic code allows alternate nucleotide sequences to be synthesized which
10 will encode FKSG79 having, for example, an amino acid sequence shown in SEQ ID NO: 2 or a biologically active variant thereof.

Extending Polynucleotides

Various PCR-based methods can be used to extend nucleic acid sequences encoding human FKSG79, for example to detect upstream sequences of FKSG79 gene such as promoters and
15 regulatory elements. For example, restriction-site PCR uses universal primers to retrieve unknown sequence adjacent to a known locus. Genomic DNA is first amplified in the presence of a primer to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA
20 polymerase and sequenced using reverse transcriptase.

Inverse PCR also can be used to amplify or extend sequences using divergent primers based on a known region. Primers can be designed using commercially available software, such as OLIGO

4.06 Primer Analysis software (National Biosciences Inc., Plymouth, Minn.), to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72°C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Another method which can be used is capture PCR, which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA. In this method, multiple restriction enzyme digestions and ligations also can be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Randomly-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries can be useful for extension of sequence into 5' non-transcribed regulatory regions.

Commercially available capillary electrophoresis systems can be used to analyze the size or confirm the nucleotide sequence of PCR or sequencing products. For example, capillary sequencing can employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity can be converted to electrical signal using appropriate equipment and software (*e.g.*, GENOTYPER and Sequence NAVIGATOR, Perkin Elmer), and the entire process from loading of samples to computer analysis and electronic data display can be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

Obtaining Polypeptides

FKSG79 can be obtained, for example, by purification from human cells, by expression of FKSG79 polynucleotides, or by direct chemical synthesis.

Protein Purification

FKSG79 can be purified from any human cell which expresses the receptor, including those which have been transfected with expression constructs which express FKSG79. A purified FKSG79 is

separated from other compounds which normally associate with FKSG79 in the cell, such as certain proteins, carbohydrates, or lipids, using methods well-known in the art. Such methods include, but are not limited to, size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and preparative gel electrophoresis.

5 *Expression of FKSG79 Polynucleotides*

To express FKSG79, FKSG79 polynucleotides can be inserted into an expression vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art can be used to construct expression vectors containing sequences encoding FKSG79 and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination.

A variety of expression vector/host systems can be utilized to contain and express sequences encoding FKSG79. These include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors, insect cell systems infected with virus expression vectors (*e.g.*, baculovirus), plant cell systems transformed with virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (*e.g.*, Ti or pBR322 plasmids), or animal cell systems.

The control elements or regulatory sequences are those non-translated regions of the vector - enhancers, promoters, 5' and 3' untranslated regions -- which interact with host cellular proteins to carry out transcription and translation. Such elements can vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, can be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or pSPORT1 plasmid (Life Technologies) and the like can be used. The baculovirus polyhedrin promoter can be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (*e.g.*, heat shock, RUBISCO, and storage protein genes) or from plant viruses (*e.g.*, viral promoters or leader sequences) can be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of a nucleotide sequence encoding FKSG79, vectors based on SV40 or EBV can be used with an appropriate selectable marker.

Bacterial and Yeast Expression Systems

In bacterial systems, a number of expression vectors can be selected. For example, when a large quantity of FKSG79 is needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified can be used. Such vectors include, but are not limited to, multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene). In a BLUESCRIPT vector, a sequence encoding FKSG79 can be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced. pIN vectors or pGEX vectors (Promega, Madison, Wis.) also can be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems can be designed to include heparin, thrombin, or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

Plant and Insect Expression Systems

If plant expression vectors are used, the expression of sequences encoding FKSG79 can be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV can be used alone or in combination with the omega leader sequence from TMV. Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters can be used. These constructs can be introduced into plant cells by direct DNA transformation or by pathogen-mediated transfection.

An insect system also can be used to express FKSG79. For example, in one such system *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. Sequences encoding FKSG79 can be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of FKSG79 will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses can then be used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which FKSG79 can be expressed.

Mammalian Expression Systems

A number of viral-based expression systems can be used to express FKSG79 in mammalian host cells. For example, if an adenovirus is used as an expression vector, sequences encoding FKSG79

can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome can be used to obtain a viable virus which is capable of expressing FKSG79 in infected host cells [Engelhard, 1994]. If desired, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, can be used to increase expression in mammalian host cells.

Human artificial chromosomes (HACs) also can be used to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of 6M to 10M are constructed and delivered to cells via conventional delivery methods (*e.g.*, liposomes, polycationic amino polymers, or vesicles). Specific initiation signals also can be used to achieve more efficient translation of sequences encoding FKSG79. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding FKSG79, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals (including the ATG initiation codon) should be provided. The initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons can be of various origins, both natural and synthetic.

Host Cells

A host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed FKSG79 in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the polypeptide also can be used to facilitate correct insertion, folding and/or function. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (*e.g.*, CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; 10801 University Boulevard, Manassas, VA 20110-2209) and can be chosen to ensure the correct modification and processing of the foreign protein.

Stable expression is preferred for long-term, high-yield production of recombinant proteins. For example, cell lines which stably express FKSG79 can be transformed using expression vectors which can contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells can be allowed to grow for 1-2 days in an enriched medium before they are switched to a selective medium. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced

FKSG79 sequences. Resistant clones of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. Any number of selection systems can be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase [Logan, (1984)] and adenine phosphoribosyltransferase [Wigler, (1977)] genes which can be employed in *tk* or *aprt* cells, respectively. Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate [Lowy, (1980)], *npt* confers resistance to the aminoglycosides, neomycin and G-418 [Wigler, (1980)], and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively [Colbere-Garapin, 1981]. Additional selectable genes have been described. For example, *trpB* allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine. Visible markers such as anthocyanins, β -glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, can be used to identify transformants and to quantify the amount of transient or stable protein expression attributable to a specific vector system

15 *Detecting Polypeptide Expression*

Although the presence of marker gene expression suggests that a FKSG79 polynucleotide is also present, its presence and expression may need to be confirmed. For example, if a sequence encoding FKSG79 is inserted within a marker gene sequence, transformed cells containing sequences which encode FKSG79 can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding FKSG79 under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of FKSG79 polynucleotide.

Alternatively, host cells which contain a FKSG79 polynucleotide and which express FKSG79 can be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip-based technologies for the detection and/or quantification of nucleic acid or protein. For example, the presence of a polynucleotide sequence encoding FKSG79 can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding FKSG79. Nucleic acid amplification-based assays involve the use of oligonucleotides selected from sequences encoding FKSG79 to detect transformants which contain a FKSG79 polynucleotide.

A variety of protocols for detecting and measuring the expression of FKSG79, using either polyclonal or monoclonal antibodies specific for the polypeptide, are known in the art. Examples

include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay using monoclonal antibodies reactive to two non-interfering epitopes on FKSG79 can be used, or a competitive binding assay can be employed.

5 A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding FKSG79 include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, sequences encoding FKSG79 can be cloned into a vector for the production of an
10 mRNA probe. Such vectors are known in the art, are commercially available, and can be used to synthesize RNA probes *in vitro* by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Pharmacia Biotech, Promega, and US Biochemical). Suitable reporter molecules or labels which can be used for ease of detection include
15 radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Expression and Purification of Polypeptides

Host cells transformed with FKSG79 polynucleotides can be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The polypeptide produced by a
20 transformed cell can be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing FKSG79 polynucleotides can be designed to contain signal sequences which direct secretion of soluble FKSG79 through a prokaryotic or eukaryotic cell membrane or which direct the membrane insertion of membrane-bound FKSG79.

25 As discussed above, other constructions can be used to join a sequence encoding FKSG79 to a nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain
30 utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). Inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and FKSG79 also can be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing FKSG79 and 6 histidine residues preceding a thioredoxin or an enterokinase cleavage

site. The histidine residues facilitate purification by IMAC (immobilized metal ion affinity chromatography) Maddox, (1983)], while the enterokinase cleavage site provides a means for purifying FKSG79 from the fusion protein [Porath, (1992)].

Chemical Synthesis

5 Sequences encoding FKSG79 can be synthesized, in whole or in part, using chemical methods well known in the art. Alternatively, FKSG79 itself can be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques. Protein synthesis can either be performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied Biosystems 431A Peptide
10 Synthesizer (Perkin Elmer). Optionally, fragments of FKSG79 can be separately synthesized and combined using chemical methods to produce a full-length molecule.

The newly synthesized peptide can be substantially purified by preparative high performance liquid chromatography. The composition of a synthetic FKSG79 can be confirmed by amino acid analysis or sequencing. Additionally, any portion of the amino acid sequence of FKSG79 can be
15 altered during direct synthesis and/or combined using chemical methods with sequences from other proteins to produce a variant polypeptide or a fusion protein.

Production of Altered Polypeptides

As will be understood by those of skill in the art, it may be advantageous to produce FKSG79 polynucleotides possessing non-naturally occurring codons. For example, codons preferred by a
20 particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences referred to herein can be engineered using methods generally known in the art to alter FKSG79 polynucleotides for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the polypeptide or mRNA
25 product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides can be used to engineer the nucleotide sequences. For example, site-directed mutagenesis can be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

Antibodies

Any type of antibody known in the art can be generated to bind specifically to an epitope of FKSG79.

5 “Antibody” as used herein includes intact immunoglobulin molecules, as well as fragments thereof, such as Fab, F(ab')₂, and Fv, which are capable of binding an epitope of FKSG79. Typically, at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope. However, epitopes which involve non-contiguous amino acids may require more, *e.g.*, at least 15, 25, or 50 amino acid. An antibody which specifically binds to an epitope of FKSG79 can be used therapeutically, as well as in immunochemical assays, such as Western blots, ELISAs, 10 radioimmunoassays, immunohistochemical assays, immunoprecipitations, or other immunochemical assays known in the art. Various immunoassays can be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays are well known in the art. Such immunoassays typically involve the measurement of complex formation between an immunogen and an antibody which specifically binds to the 15 FKSG79 immunogen.

Typically, an antibody which specifically binds to FKSG79 provides a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in an immunochemical assay. Preferably, antibodies which specifically bind to FKSG79 do not detect other proteins in immunochemical assays and can immunoprecipitate FKSG79 from solution.

20 FKSG79 can be used to immunize a mammal, such as a mouse, rat, rabbit, guinea pig, monkey, or human, to produce polyclonal antibodies. If desired, FKSG79 can be conjugated to a carrier protein, such as bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin. Depending on the host species, various adjuvants can be used to increase the immunological response. Such adjuvants include, but are not limited to, Freund's adjuvant, mineral gels (*e.g.*, aluminum 25 hydroxide), and surface active substances (*e.g.*, lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol). Among adjuvants used in humans, BCG (*bacilli Calmette-Guerin*) and *Corynebacterium parvum* are especially useful.

Monoclonal antibodies which specifically bind to FKSG79 can be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These 30 techniques include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique [Roberge, (1995)].

In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. Monoclonal and other antibodies also can be "humanized" to prevent a patient from mounting an immune response against the antibody when it is used therapeutically. Such antibodies may be sufficiently similar in sequence to human antibodies to be used directly in therapy or may require alteration of a few key residues. Sequence differences between rodent antibodies and human sequences can be minimized by replacing residues which differ from those in the human sequences by site directed mutagenesis of individual residues or by grating of entire complementarity determining regions. Antibodies which specifically bind to FKSG79 can contain antigen binding sites which are either partially or fully humanized, as disclosed in U.S. 5,565,332.

Alternatively, techniques described for the production of single chain antibodies can be adapted using methods known in the art to produce single chain antibodies which specifically bind to FKSG79. Antibodies with related specificity, but of distinct idiotypic composition, can be generated by chain shuffling from random combinatorial immunoglobulin libraries. Single-chain antibodies also can be constructed using a DNA amplification method, such as PCR, using hybridoma cDNA as a template. Single-chain antibodies can be mono- or bispecific, and can be bivalent or tetravalent. Construction of tetravalent, bispecific single-chain antibodies is taught. A nucleotide sequence encoding a single-chain antibody can be constructed using manual or automated nucleotide synthesis, cloned into an expression construct using standard recombinant DNA methods, and introduced into a cell to express the coding sequence, as described below. Alternatively, single-chain antibodies can be produced directly using, for example, filamentous phage technology.

Antibodies which specifically bind to FKSG79 also can be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents. Other types of antibodies can be constructed and used therapeutically in methods of the invention. For example, chimeric antibodies can be constructed as disclosed in WO 93/03151. Binding proteins which are derived from immunoglobulins and which are multivalent and multispecific, such as the "diabodies" described in WO 94/13804, also can be prepared.

Antibodies according to the invention can be purified by methods well known in the art. For example, antibodies can be affinity purified by passage over a column to which FKSG79 is bound. The bound antibodies can then be eluted from the column using a buffer with a high salt concentration.

Antisense Oligonucleotides

Antisense oligonucleotides are nucleotide sequences which are complementary to a specific DNA or RNA sequence. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form complexes and block either transcription or translation. Preferably, an antisense oligonucleotide is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences also can be used. Antisense oligonucleotide molecules can be provided in a DNA construct and introduced into a cell as described above to decrease the level of FKSG79 gene products in the cell.

Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides, or a combination of both. Oligonucleotides can be synthesized manually or by an automated synthesizer, by covalently linking the 5' end of one nucleotide with the 3' end of another nucleotide with non-phosphodiester internucleotide linkages such as alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, alkylphosphonates, phosphoramidates, phosphate esters, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters.

Modifications of FKSG79 gene expression can be obtained by designing antisense oligonucleotides which will form duplexes to the control, 5', or regulatory regions of the FKSG79 gene. Oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or chaperons. Therapeutic advances using triplex DNA have been described in the literature [Nicholls, (1993)]. An antisense oligonucleotide also can be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Precise complementarity is not required for successful complex formation between an antisense oligonucleotide and the complementary sequence of a FKSG79 polynucleotide. Antisense oligonucleotides which comprise, for example, 2, 3, 4, or 5 or more stretches of contiguous nucleotides which are precisely complementary to a FKSG79 polynucleotide, each separated by a stretch of contiguous nucleotides which are not complementary to adjacent FKSG79 nucleotides, can provide sufficient targeting specificity for FKSG79 mRNA. Preferably, each stretch of complementary contiguous nucleotides is at least 4, 5, 6, 7, or 8 or more nucleotides in length. Non-complementary intervening sequences are preferably 1, 2, 3, or 4 nucleotides in length. One skilled in the art can easily use the calculated melting point of an antisense-sense pair to determine the degree of mismatching which will be tolerated between a particular antisense oligonucleotide and a particular FKSG79 polynucleotide sequence. Antisense oligonucleotides can be modified

without affecting their ability to hybridize to a FKSG79 polynucleotide. These modifications can be internal or at one or both ends of the antisense molecule. For example, internucleoside phosphate linkages can be modified by adding cholesteryl or diamine moieties with varying numbers of carbon residues between the amino groups and terminal ribose. Modified bases and/or sugars, such as arabinose instead of ribose, or a 3', 5'-substituted oligonucleotide in which the 3' hydroxyl group or the 5' phosphate group are substituted, also can be employed in a modified antisense oligonucleotide. These modified oligonucleotides can be prepared by methods well known in the art.

Ribozymes

Ribozymes are RNA molecules with catalytic activity [Uhlmann, (1987)]. Ribozymes can be used to inhibit gene function by cleaving an RNA sequence, as is known in the art. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of specific nucleotide sequences. The coding sequence of a FKSG79 polynucleotide can be used to generate ribozymes which will specifically bind to mRNA transcribed from a FKSG79 polynucleotide. Methods of designing and constructing ribozymes which can cleave other RNA molecules in trans in a highly sequence specific manner have been developed and described in the art. For example, the cleavage activity of ribozymes can be targeted to specific RNAs by engineering a discrete "hybridization" region into the ribozyme. The hybridization region contains a sequence complementary to the target RNA and thus specifically hybridizes with the target RNA.

Specific ribozyme cleavage sites within a FKSG79 RNA target can be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target RNA containing the cleavage site can be evaluated for secondary structural features which may render the target inoperable. Suitability of candidate FKSG79 RNA targets also can be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays. The nucleotide sequences shown in SEQ ID NO: 1 and its complement provide sources of suitable hybridization region sequences. Longer complementary sequences can be used to increase the affinity of the hybridization sequence for the target. The hybridizing and cleavage regions of the ribozyme can be integrally related such that upon hybridizing to the target RNA through the complementary regions, the catalytic region of the ribozyme can cleave the target.

Ribozymes can be introduced into cells as part of a DNA construct. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium phosphate precipitation, can be used to introduce a ribozyme-containing DNA construct into cells in which it is desired to decrease FKSG79 expression. Alternatively, if it is desired that the cells stably retain the DNA construct, the construct can be supplied on a plasmid and maintained as a separate element or integrated into the genome of the cells, as is known in the art. A ribozyme-encoding DNA construct can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of ribozymes in the cells (U.S. 5,641,673). Ribozymes also can be engineered to provide an additional level of regulation, so that destruction of mRNA occurs only when both a ribozyme and a target gene are induced in the cells.

Screening / Screening Assays

Regulators

Regulators as used herein, refer to compounds that affect the activity of a FKSG79 in vivo and/or in vivo. Regulators can be agonists and antagonists of a FKSG79 polypeptide and can be compounds that exert their effect on the FKSG79 activity via the expression, via post-translational modifications or by other means. Agonists of FKSG79 are molecules which, when bound to FKSG79, increase or prolong the activity of FKSG79. Agonists of FKSG79 include proteins, nucleic acids, carbohydrates, small molecules, or any other molecule which activate FKSG79. Antagonists of FKSG79 are molecules which, when bound to FKSG79, decrease the amount or the duration of the activity of FKSG79. Antagonists include proteins, nucleic acids, carbohydrates, antibodies, small molecules, or any other molecule which decrease the activity of FKSG79.

The term "modulate", as it appears herein, refers to a change in the activity of FKSG79 polypeptide. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of FKSG79.

As used herein, the terms "specific binding" or "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon the presence of a particular structure of the protein recognized by the binding molecule (i.e., the antigenic determinant or epitope). For example, if an antibody is specific for epitope "A" the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The invention provides methods (also referred to herein as "screening assays") for identifying compounds which can be used for the treatment of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases. The methods entail the identification of candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other molecules) which bind to FKSG79 and/or have a stimulatory or inhibitory effect on the biological activity of FKSG79 or its expression and then determining which of these compounds have an effect on symptoms or diseases regarding the cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in an *in vivo* assay.

Candidate or test compounds or agents which bind to FKSG79 and/or have a stimulatory or inhibitory effect on the activity or the expression of FKSG79 are identified either in assays that employ cells which express FKSG79 on the cell surface (cell-based assays) or in assays with isolated FKSG79 (cell-free assays). The various assays can employ a variety of variants of FKSG79 (e.g., full-length FKSG79, a biologically active fragment of FKSG79, or a fusion protein which includes all or a portion of FKSG79). Moreover, FKSG79 can be derived from any suitable mammalian species (e.g., human FKSG79, rat FKSG79 or murine FKSG79). The assay can be a binding assay entailing direct or indirect measurement of the binding of a test compound or a known FKSG79 ligand to FKSG79. The assay can also be an activity assay entailing direct or indirect measurement of the activity of FKSG79. The assay can also be an expression assay entailing direct or indirect measurement of the expression of FKSG79 mRNA or FKSG79 protein. The various screening assays are combined with an *in vivo* assay entailing measuring the effect of the test compound on the symptoms of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a membrane-bound (cell surface expressed) form of FKSG79. Such assays can employ full-length FKSG79, a biologically active fragment of FKSG79, or a fusion protein which includes all or a portion of FKSG79. As described in greater detail below, the test compound can be obtained by any suitable means, e.g., from conventional compound libraries. Determining the ability of the test compound to bind to a membrane-bound form of FKSG79 can be accomplished, for example, by coupling the test compound with a

radioisotope or enzymatic label such that binding of the test compound to the FKSG79 -expressing cell can be measured by detecting the labeled compound in a complex. For example, the test compound can be labelled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting. Alternatively, the test compound can be enzymatically labelled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

In a competitive binding format, the assay comprises contacting FKSG79 expressing cell with a known compound which binds to FKSG79 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the FKSG79 expressing cell, wherein determining the ability of the test compound to interact with the FKSG79 expressing cell comprises determining the ability of the test compound to preferentially bind the FKSG79 expressing cell as compared to the known compound.

In another embodiment, the assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of FKSG79 (e.g., full-length FKSG79, a biologically active fragment of FKSG79, or a fusion protein which includes all or a portion of FKSG79) expressed on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the membrane-bound form of FKSG79. Determining the ability of the test compound to modulate the activity of the membrane-bound form of FKSG79 can be accomplished by any method suitable for measuring the activity of FKSG79, e.g., any method suitable for measuring the activity of a G-protein coupled receptor or other seven-transmembrane receptor (described in greater detail below). The activity of a seven-transmembrane receptor can be measured in a number of ways, not all of which are suitable for any given receptor. Among the measures of activity are: alteration in intracellular Ca^{2+} concentration, activation of phospholipase C, alteration in intracellular inositol triphosphate (IP_3) concentration, alteration in intracellular diacylglycerol (DAG) concentration, and alteration in intracellular adenosine cyclic 3', 5'-monophosphate (cAMP) concentration.

Determining the ability of the test compound to modulate the activity of FKSG79 can be accomplished, for example, by determining the ability of FKSG79 to bind to or interact with a target molecule. The target molecule can be a molecule with which FKSG79 binds or interacts with in nature, for example, a molecule on the surface of a cell which expresses FKSG79, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. The target molecule can be a component of a signal transduction pathway which facilitates transduction of an

extracellular signal (e.g., a signal generated by binding of a FKSG79 ligand, through the cell membrane and into the cell. The target FKSG79 molecule can be, for example, a second intracellular protein which has catalytic activity or a protein which facilitates the association of downstream signaling molecules with FKSG79.

5 Determining the ability of FKSG79 to bind to or interact with a target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of a polypeptide of the invention to bind to or interact with a target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular
10 second messenger of the target (e.g., intracellular Ca^{2+} , diacylglycerol, IP_3 , etc.), detecting catalytic/enzymatic activity of the target on an appropriate substrate, detecting the induction of a reporter gene (e.g., a regulatory element that is responsive to a polypeptide of the invention operably linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response.

15 The present invention also includes cell-free assays. Such assays involve contacting a form of FKSG79 (e.g., full-length FKSG79, a biologically active fragment of FKSG79, or a fusion protein comprising all or a portion of FKSG79) with a test compound and determining the ability of the test compound to bind to FKSG79. Binding of the test compound to FKSG79 can be determined either directly or indirectly as described above. In one embodiment, the assay includes contacting
20 FKSG79 with a known compound which binds FKSG79 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with FKSG79, wherein determining the ability of the test compound to interact with FKSG79 comprises determining the ability of the test compound to preferentially bind to FKSG79 as compared to the known compound.

25 The cell-free assays of the present invention are amenable to use of either a membrane-bound form of FKSG79 or a soluble fragment thereof. In the case of cell-free assays comprising the membrane-bound form of the polypeptide, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of the polypeptide is maintained in solution. Examples of such solubilizing agents include but are not limited to non-ionic detergents such as n-octylglucoside, n-
30 dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton X-100, Triton X-114, Thesit, Isotridecypoly(ethylene glycol ether)_n, 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl=N,N-dimethyl-3-ammonio-1-propane sulfonate.

In various embodiments of the above assay methods of the present invention, it may be desirable to immobilize FKSG79 (or a FKSG79 target molecule) to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to FKSG79, or interaction of FKSG79 with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase (GST) fusion proteins or glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical; St. Louis, Mo.) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or FKSG79, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components and complex formation is measured either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of binding or activity of FKSG79 can be determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either FKSG79 or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated polypeptide of the invention or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals; Rockford, Ill.), and immobilized in the wells of streptavidin-coated plates (Pierce Chemical). Alternatively, antibodies reactive with FKSG79 or target molecules but which do not interfere with binding of the polypeptide of the invention to its target molecule can be derivatized to the wells of the plate, and unbound target or polypeptide of the invention trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with FKSG79 or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with FKSG79 or target molecule.

The screening assay can also involve monitoring the expression of FKSG79. For example, regulators of expression of FKSG79 can be identified in a method in which a cell is contacted with a candidate compound and the expression of FKSG79 protein or mRNA in the cell is determined. The level of expression of FKSG79 protein or mRNA the presence of the candidate compound is compared to the level of expression of FKSG79 protein or mRNA in the absence of the candidate

compound. The candidate compound can then be identified as a regulator of expression of FKSG79 based on this comparison. For example, when expression of FKSG79 protein or mRNA protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of FKSG79 protein or mRNA expression. Alternatively, when expression of FKSG79 protein or mRNA is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of FKSG79 protein or mRNA expression. The level of FKSG79 protein or mRNA expression in the cells can be determined by methods described below.

10 *Binding Assays*

For binding assays, the test compound is preferably a small molecule which binds to and occupies the active site of FKSG79 polypeptide, thereby making the ligand binding site inaccessible to substrate such that normal biological activity is prevented. Examples of such small molecules include, but are not limited to, small peptides or peptide-like molecules. Potential ligands which bind to a polypeptide of the invention include, but are not limited to, the natural ligands of known FKSG79 GPCRs and analogues or derivatives thereof.

In binding assays, either the test compound or the FKSG79 polypeptide can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase. Detection of a test compound which is bound to FKSG79 polypeptide can then be accomplished, for example, by direct counting of radioemission, by scintillation counting, or by determining conversion of an appropriate substrate to a detectable product. Alternatively, binding of a test compound to a FKSG79 polypeptide can be determined without labeling either of the interactants. For example, a microphysiometer can be used to detect binding of a test compound with a FKSG79 polypeptide. A microphysiometer (*e.g.*, Cytosensor™) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a test compound and FKSG79 [Haseloff, (1988)].

Determining the ability of a test compound to bind to FKSG79 also can be accomplished using a technology such as real-time Bimolecular Interaction Analysis (BIA) [McConnell, (1992); Sjolander, (1991)]. BIA is a technology for studying biospecific interactions in real time, without labeling any of the interactants (*e.g.*, BIAcore™). Changes in the optical phenomenon surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

In yet another aspect of the invention, a FKSG79-like polypeptide can be used as a "bait protein" in a two-hybrid assay or three-hybrid assay [Szabo, (1995); U.S. 5,283,317], to identify other proteins which bind to or interact with FKSG79 and modulate its activity.

5 The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. For example, in one construct, polynucleotide encoding FKSG79 can be fused to a polynucleotide encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct a DNA sequence that encodes an unidentified protein ("prey" or "sample") can be fused to a polynucleotide that codes for the activation domain of the known transcription
10 factor. If the "bait" and the "prey" proteins are able to interact *in vivo* to form an protein-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ), which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected, and cell colonies containing the functional
15 transcription factor can be isolated and used to obtain the DNA sequence encoding the protein which interacts with FKSG79.

It may be desirable to immobilize either the FKSG79 (or polynucleotide) or the test compound to facilitate separation of the bound form from unbound forms of one or both of the interactants, as well as to accommodate automation of the assay. Thus, either the FKSG79-like polypeptide (or
20 polynucleotide) or the test compound can be bound to a solid support. Suitable solid supports include, but are not limited to, glass or plastic slides, tissue culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex, polystyrene, or glass beads). Any method known in the art can be used to attach FKSG79-like polypeptide (or polynucleotide) or test compound to a solid support, including use of covalent and non-covalent
25 linkages, passive absorption, or pairs of binding moieties attached respectively to the polypeptide (or polynucleotide) or test compound and the solid support. Test compounds are preferably bound to the solid support in an array, so that the location of individual test compounds can be tracked. Binding of a test compound to FKSG79 (or a polynucleotide encoding for FKSG79) can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include
30 microtiter plates, test tubes, and microcentrifuge tubes.

In one embodiment, FKSG79 is a fusion protein comprising a domain that allows binding of FKSG79 to a solid support. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test

compound and the non-adsorbed FKSG79; the mixture is then incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components. Binding of the interactants can be determined either directly or indirectly, as described above.
5 Alternatively, the complexes can be dissociated from the solid support before binding is determined.

Other techniques for immobilizing proteins or polynucleotides on a solid support also can be used in the screening assays of the invention. For example, either FKSG79 (or a polynucleotide encoding FKSG79) or a test compound can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated FKSG79 (or a polynucleotide encoding biotinylated FKSG79) or test
10 compounds can be prepared from biotin-NHS (N-hydroxysuccinimide) using techniques well known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.) and immobilized in the wells of streptavidin-coated plates (Pierce Chemical). Alternatively, antibodies which specifically bind to FKSG79, polynucleotide, or a test compound, but which do not interfere with a desired
15 binding site, such as the active site of FKSG79, can be derivatized to the wells of the plate. Unbound target or protein can be trapped in the wells by antibody conjugation.

Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies which specifically bind to FKSG79 polypeptide or test compound, enzyme-linked assays which rely on
20 detecting an activity of FKSG79 polypeptide, and SDS gel electrophoresis under non-reducing conditions.

Screening for test compounds which bind to a FKSG79 polypeptide or polynucleotide also can be carried out in an intact cell. Any cell which comprises a FKSG79 polypeptide or polynucleotide can be used in a cell-based assay system. A FKSG79 polynucleotide can be naturally occurring in
25 the cell or can be introduced using techniques such as those described above. Binding of the test compound to FKSG79 or a polynucleotide encoding FKSG79 is determined as described above.

Functional Assays

Test compounds can be tested for the ability to increase or decrease FKSG79 activity of a FKSG79 polypeptide. The FKSG79 activity can be measured, for example, using methods described in the
30 specific examples, below. FKSG79 activity can be measured after contacting either a purified FKSG79, a cell membrane preparation, or an intact cell with a test compound. A test compound which decreases FKSG79 activity by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential agent for decreasing FKSG79 activity. A test

compound which increases FKSG79 activity by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential agent for increasing FKSG79 activity.

One such screening procedure involves the use of melanophores which are transfected to express FKSG79. Such a screening technique is described in PCT WO 92/01810 published Feb. 6, 1992.

5 Thus, for example, such an assay may be employed for screening for a compound which inhibits activation of the receptor polypeptide of the present invention by contacting the melanophore cells which encode the receptor with both the receptor ligand and a compound to be screened. Inhibition of the signal generated by the ligand indicates that a compound is a potential antagonist for the receptor, *i.e.*, inhibits activation of the receptor. The screen may be employed for
10 identifying a compound which activates the receptor by contacting such cells with compounds to be screened and determining whether each compound generates a signal, *i.e.*, activates the receptor.

Other screening techniques include the use of cells which express FKSG79 (for example, transfected CHO cells) in a system which measures extracellular pH changes caused by receptor
15 activation [Iwabuchi, (1993)]. For example, compounds may be contacted with a cell which expresses the receptor polypeptide of the present invention and a second messenger response, *e.g.*, signal transduction or pH changes, can be measured to determine whether the potential compound activates or inhibits the receptor. Another such screening technique involves introducing RNA
20 encoding FKSG79 into *Xenopus* oocytes to transiently express the receptor. The receptor oocytes can then be contacted with the receptor ligand and a compound to be screened, followed by detection of inhibition or activation of a calcium signal in the case of screening for compounds which are thought to inhibit activation of the receptor.

Another screening technique involves expressing FKSG79 in cells in which the receptor is linked to a phospholipase C or D. Such cells include endothelial cells, smooth muscle cells, embryonic
25 kidney cells, etc. The screening may be accomplished as described above by quantifying the degree of activation of the receptor from changes in the phospholipase activity.

Gene Expression

In another embodiment, test compounds which increase or decrease FKSG79 gene expression are identified. As used herein, the term "correlates with expression of a polynucleotide" indicates that
30 the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding FKSG79, by northern analysis or real-time PCR is indicative of the presence of nucleic acids encoding FKSG79 in a sample, and thereby correlates with expression of the transcript from the polynucleotide encoding FKSG79. The term "microarray", as used herein, refers to an array of

distinct polynucleotides or oligonucleotides arrayed on a substrate, such as paper, nylon or any other type of membrane, filter, chip, glass slide, or any other suitable solid support. A FKSG79 polynucleotide is contacted with a test compound, and the expression of an RNA or polypeptide product of FKSG79 polynucleotide is determined. The level of expression of appropriate mRNA or polypeptide in the presence of the test compound is compared to the level of expression of mRNA or polypeptide in the absence of the test compound. The test compound can then be identified as a regulator of expression based on this comparison. For example, when expression of mRNA or polypeptide is greater in the presence of the test compound than in its absence, the test compound is identified as a stimulator or enhancer of the mRNA or polypeptide expression. Alternatively, when expression of the mRNA or polypeptide is less in the presence of the test compound than in its absence, the test compound is identified as an inhibitor of the mRNA or polypeptide expression.

The level of FKSG79 mRNA or polypeptide expression in the cells can be determined by methods well known in the art for detecting mRNA or polypeptide. Either qualitative or quantitative methods can be used. The presence of polypeptide products of FKSG79 polynucleotide can be determined, for example, using a variety of techniques known in the art, including immunochemical methods such as radioimmunoassay, Western blotting, and immunohistochemistry. Alternatively, polypeptide synthesis can be determined *in vivo*, in a cell culture, or in an *in vitro* translation system by detecting incorporation of labelled amino acids into FKSG79.

Such screening can be carried out either in a cell-free assay system or in an intact cell. Any cell which expresses FKSG79 polynucleotide can be used in a cell-based assay system. The FKSG79 polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Either a primary culture or an established cell line can be used.

Test Compounds

Suitable test compounds for use in the screening assays of the invention can be obtained from any suitable source, e.g., conventional compound libraries. The test compounds can also be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds [Lam, (1997)]. Examples of methods for the synthesis of molecular libraries can be found in the art. Libraries of compounds may be presented in solution or on beads, bacteria, spores, plasmids or phage.

Modeling of Regulators

Computer modeling and searching technologies permit identification of compounds, or the improvement of already identified compounds, that can modulate FKSG79 expression or activity. Having identified such a compound or composition, the active sites or regions are identified. Such active sites might typically be ligand binding sites, such as the interaction domain of the ligand with FKSG79. The active site can be identified using methods known in the art including, for example, from the amino acid sequences of peptides, from the nucleotide sequences of nucleic acids, or from study of complexes of the relevant compound or composition with its natural ligand. In the latter case, chemical or X-ray crystallographic methods can be used to find the active site by finding where on the factor the complexed ligand is found.

Next, the three dimensional geometric structure of the active site is determined. This can be done by known methods, including X-ray crystallography, which can determine a complete molecular structure. On the other hand, solid or liquid phase NMR can be used to determine certain intramolecular distances. Any other experimental method of structure determination can be used to obtain partial or complete geometric structures. The geometric structures may be measured with a complexed ligand, natural or artificial, which may increase the accuracy of the active site structure determined.

If an incomplete or insufficiently accurate structure is determined, the methods of computer based numerical modeling can be used to complete the structure or improve its accuracy. Any recognized modeling method may be used, including parameterized models specific to particular biopolymers such as proteins or nucleic acids, molecular dynamics models based on computing molecular motions, statistical mechanics models based on thermal ensembles, or combined models. For most types of models, standard molecular force fields, representing the forces between constituent atoms and groups, are necessary, and can be selected from force fields known in physical chemistry. The incomplete or less accurate experimental structures can serve as constraints on the complete and more accurate structures computed by these modeling methods.

Finally, having determined the structure of the active site, either experimentally, by modeling, or by a combination, candidate modulating compounds can be identified by searching databases containing compounds along with information on their molecular structure. Such a search seeks compounds having structures that match the determined active site structure and that interact with the groups defining the active site. Such a search can be manual, but is preferably computer assisted. These compounds found from this search are potential FKSG79 modulating compounds.

Alternatively, these methods can be used to identify improved modulating compounds from an already known modulating compound or ligand. The composition of the known compound can be modified and the structural effects of modification can be determined using the experimental and computer modeling methods described above applied to the new composition. The altered structure is then compared to the active site structure of the compound to determine if an improved fit or interaction results. In this manner systematic variations in composition, such as by varying side groups, can be quickly evaluated to obtain modified modulating compounds or ligands of improved specificity or activity.

Therapeutic Indications and Methods

It was found by the present applicant that FKSG79 is expressed in various human tissues.

Neurology

CNS disorders include disorders of the central nervous system as well as disorders of the peripheral nervous system.

CNS disorders include, but are not limited to brain injuries, cerebrovascular diseases and their consequences, Parkinson's disease, corticobasal degeneration, motor neuron disease, dementia, including ALS, multiple sclerosis, traumatic brain injury, stroke, post-stroke, post-traumatic brain injury, and small-vessel cerebrovascular disease. Dementias, such as Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia and Parkinsonism linked to chromosome 17, frontotemporal dementias, including Pick's disease, progressive nuclear palsy, corticobasal degeneration, Huntington's disease, thalamic degeneration, Creutzfeld-Jakob dementia, HIV dementia, schizophrenia with dementia, and Korsakoff's psychosis, within the meaning of the definition are also considered to be CNS disorders.

Similarly, cognitive-related disorders, such as mild cognitive impairment, age-associated memory impairment, age-related cognitive decline, vascular cognitive impairment, attention deficit disorders, attention deficit hyperactivity disorders, and memory disturbances in children with learning disabilities are also considered to be CNS disorders.

Pain, within the meaning of this definition, is also considered to be a CNS disorder. Pain can be associated with CNS disorders, such as multiple sclerosis, spinal cord injury, sciatica, failed back surgery syndrome, traumatic brain injury, epilepsy, Parkinson's disease, post-stroke, and vascular lesions in the brain and spinal cord (e.g., infarct, hemorrhage, vascular malformation). Non-central neuropathic pain includes that associated with post mastectomy pain, phantom feeling, reflex sympathetic dystrophy (RSD), trigeminal neuralgiaradioculopathy, post-surgical pain, HIV/AIDS

related pain, cancer pain, metabolic neuropathies (e.g., diabetic neuropathy, vasculitic neuropathy secondary to connective tissue disease), paraneoplastic polyneuropathy associated, for example, with carcinoma of lung, or leukemia, or lymphoma, or carcinoma of prostate, colon or stomach, trigeminal neuralgia, cranial neuralgias, and post-herpetic neuralgia. Pain associated with peripheral nerve damage, central pain (i.e. due to cerebral ischemia) and various chronic pain i.e., lumbago, back pain (low back pain), inflammatory and/or rheumatic pain. Headache pain (for example, migraine with aura, migraine without aura, and other migraine disorders), episodic and chronic tension-type headache, tension-type like headache, cluster headache, and chronic paroxysmal hemicrania are also CNS disorders.

Visceral pain such as pancreatitis, intestinal cystitis, dysmenorrhea, irritable Bowel syndrome, Crohn's disease, biliary colic, ureteral colic, myocardial infarction and pain syndromes of the pelvic cavity, e.g., vulvodinia, orchialgia, urethral syndrome and protatodynia are also CNS disorders.

Also considered to be a disorder of the nervous system are acute pain, for example postoperative pain, and pain after trauma.

The human FKSG79 is highly expressed in the following brain tissues: cerebral cortex, occipital lobe, substantia nigra, caudatum, hippocampus, hypothalamus. The expression in brain tissues demonstrates that the human FKSG79 or mRNA can be utilized to diagnose nervous system diseases. Additionally the activity of the human FKSG79 can be modulated to treat nervous system diseases.

Cardiovascular Disorders

Heart failure is defined as a pathophysiological state in which an abnormality of cardiac function is responsible for the failure of the heart to pump blood at a rate commensurate with the requirement of the metabolizing tissue. It includes all forms of pumping failures such as high-output and low-output, acute and chronic, right-sided or left-sided, systolic or diastolic, independent of the underlying cause.

Myocardial infarction (MI) is generally caused by an abrupt decrease in coronary blood flow that follows a thrombotic occlusion of a coronary artery previously narrowed by arteriosclerosis. MI prophylaxis (primary and secondary prevention) is included as well as the acute treatment of MI and the prevention of complications.

Ischemic diseases are conditions in which the coronary flow is restricted resulting in a perfusion which is inadequate to meet the myocardial requirement for oxygen. This group of diseases includes stable angina, unstable angina and asymptomatic ischemia.

5 Arrhythmias include all forms of atrial and ventricular tachyarrhythmias, atrial tachycardia, atrial flutter, atrial fibrillation, atrio-ventricular reentrant tachycardia, preexcitation syndrome, ventricular tachycardia, ventricular flutter, ventricular fibrillation, as well as bradycardic forms of arrhythmias.

10 Hypertensive vascular diseases include primary as well as all kinds of secondary arterial hypertension, renal, endocrine, neurogenic, others. The genes may be used as drug targets for the treatment of hypertension as well as for the prevention of all complications arising from cardiovascular diseases.

15 Peripheral vascular diseases are defined as vascular diseases in which arterial and/or venous flow is reduced resulting in an imbalance between blood supply and tissue oxygen demand. It includes chronic peripheral arterial occlusive disease (PAOD), acute arterial thrombosis and embolism, inflammatory vascular disorders, Raynaud's phenomenon and venous disorders.

20 Atherosclerosis is a cardiovascular disease in which the vessel wall is remodeled, compromising the lumen of the vessel. The atherosclerotic remodeling process involves accumulation of cells, both smooth muscle cells and monocyte/macrophage inflammatory cells, in the intima of the vessel wall. These cells take up lipid, likely from the circulation, to form a mature atherosclerotic lesion. Although the formation of these lesions is a chronic process, occurring over decades of an adult human life, the majority of the morbidity associated with atherosclerosis occurs when a lesion ruptures, releasing thrombogenic debris that rapidly occludes the artery. When such an acute event occurs in the coronary artery, myocardial infarction can ensue, and in the worst case, can result in death.

25 The formation of the atherosclerotic lesion can be considered to occur in five overlapping stages such as migration, lipid accumulation, recruitment of inflammatory cells, proliferation of vascular smooth muscle cells, and extracellular matrix deposition. Each of these processes can be shown to occur in man and in animal models of atherosclerosis, but the relative contribution of each to the pathology and clinical significance of the lesion is unclear.

30 Thus, a need exists for therapeutic methods and agents to treat cardiovascular pathologies, such as atherosclerosis and other conditions related to coronary artery disease.

Cardiovascular diseases include but are not limited to disorders of the heart and the vascular system like congestive heart failure, myocardial infarction, ischemic diseases of the heart, all kinds of atrial and ventricular arrhythmias, hypertensive vascular diseases, peripheral vascular diseases, and atherosclerosis.

5 Too high or too low levels of fats in the bloodstream, especially cholesterol, can cause long-term problems. The risk to develop atherosclerosis and coronary artery or carotid artery disease (and thus the risk of having a heart attack or stroke) increases with the total cholesterol level increasing. Nevertheless, extremely low cholesterol levels may not be healthy. Examples of disorders of lipid metabolism are hyperlipidemia (abnormally high levels of fats (cholesterol, triglycerides, or both)
10 in the blood, may be caused by family history of hyperlipidemia), obesity, a high-fat diet, lack of exercise, moderate to high alcohol consumption, cigarette smoking, poorly controlled diabetes, and an underactive thyroid gland), hereditary hyperlipidemias (type I hyperlipoproteinemia (familial hyperchylomicronemia), type II hyperlipoproteinemia (familial hypercholesterolemia), type III hyperlipoproteinemia, type IV hyperlipoproteinemia, or type V hyperlipoproteinemia),
15 hypolipoproteinemia, lipidoses (caused by abnormalities in the enzymes that metabolize fats), Gaucher's disease, Niemann-Pick disease, Fabry's disease, Wolman's disease, cerebrotendinous xanthomatosis, sitosterolemia, Refsum's disease, or Tay-Sachs disease.

Kidney disorders may lead to hypertension or hypotension. Examples for kidney problems possibly leading to hypertension are renal artery stenosis, pyelonephritis, glomerulonephritis, kidney
20 tumors, polycystic kidney disease, injury to the kidney, or radiation therapy affecting the kidney. Excessive urination may lead to hypotension.

The human FKSG79 is highly expressed in the following cardiovascular related tissues: heart, heart, heart, heart myocardial infarction, pericardium, heart atrium (right), heart atrium (left), heart ventricle (right), Purkinje fibers, interventricular septum, fetal aorta, aorta, aorta, arcus aorta, aorta
25 valve, vein, pulmonic valve, vein (saphena magna), coronary artery endothel cells, fetal liver, liver, liver liver cirrhosis, liver lupus disease, liver tumor, thrombocytes, adipose, adipose, fetal kidney, kidney, kidney, kidney tumor, renal epithelial cells, HEK 293 cells. Expression in the above mentioned tissues demonstrates that the human FKSG79 or mRNA can be utilized to diagnose of cardiovascular diseases. Additionally the activity of the human FKSG79 can be modulated to treat
30 cardiovascular diseases.

The human FKSG79 is highly expressed in liver tissues: fetal liver, liver, liver liver cirrhosis, liver lupus disease, liver tumor. Expression in liver tissues demonstrates that the human FKSG79 or mRNA can be utilized to diagnose of dyslipidemia disorders as an cardiovascular disorder.

Additionally the activity of the human FKSG79 can be modulated to treat - but not limited to - dyslipidemia disorders.

The human FKSG79 is highly expressed in adipose tissues. Expression in adipose demonstrates that the human FKSG79 or mRNA can be utilized to diagnose of dyslipidemia diseases as an cardiovascular disorder. Additionally the activity of the human FKSG79 can be modulated to treat - but not limited to - dyslipidemia diseases.

The human FKSG79 is highly expressed in kidney tissues : fetal kidney, kidney, kidney, kidney tumor, HEK 293 cells. Expression in kidney tissues demonstrates that the human FKSG79 or mRNA can be utilized to diagnose of blood pressure disorders as an cardiovascular disorder. Additionally the activity of the human FKSG79 can be modulated to treat - but not limited to - blood pressure disorders as hypertension or hypotension.

Hematological Disorders

Hematological disorders comprise diseases of the blood and all its constituents as well as diseases of organs and tissues involved in the generation or degradation of all the constituents of the blood. They include but are not limited to 1) Anemias, 2) Myeloproliferative Disorders, 3) Hemorrhagic Disorders, 4) Leukopenia, 5) Eosinophilic Disorders, 6) Leukemias, 7) Lymphomas, 8) Plasma Cell Dyscrasias, 9) Disorders of the Spleen in the course of hematological disorders. Disorders according to 1) include, but are not limited to anemias due to defective or deficient hem synthesis, deficient erythropoiesis. Disorders according to 2) include, but are not limited to polycythemia vera, tumor-associated erythrocytosis, myelofibrosis, thrombocythemia. Disorders according to 3) include, but are not limited to vasculitis, thrombocytopenia, heparin-induced thrombocytopenia, thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, hereditary and acquired disorders of platelet function, hereditary coagulation disorders. Disorders according to 4) include, but are not limited to neutropenia, lymphocytopenia. Disorders according to 5) include, but are not limited to hypereosinophilia, idiopathic hypereosinophilic syndrome. Disorders according to 6) include, but are not limited to acute myeloic leukemia, acute lymphoblastic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia, myelodysplastic syndrome. Disorders according to 7) include, but are not limited to Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, mycosis fungoides cutaneous T-cell lymphoma. Disorders according to 8) include, but are not limited to multiple myeloma, macroglobulinemia, heavy chain diseases. In extension of the preceding idiopathic thrombocytopenic purpura, iron deficiency anemia, megaloblastic anemia (vitamin B12 deficiency), aplastic anemia, thalassemia, malignant lymphoma bone marrow invasion, malignant lymphoma skin invasion, hemolytic uremic syndrome, giant platelet disease are considered to be hematological diseases too.

The human FKSG79 is highly expressed in the following tissues of the hematological system: leukocytes (peripheral blood), Jurkat (T-cells), Raji (B-cells), bone marrow, erythrocytes, lymphnode, thymus, thrombocytes, bone marrow stromal cells, bone marrow CD33+ cells, bone marrow CD34+ cells, cord blood CD34+ cells, neutrophils cord blood, T-cells peripheral blood CD8+, monocytes peripheral blood CD14+, B-cells peripheral blood CD19+, neutrophils peripheral blood, spleen, spleen liver cirrhosis. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue spleen liver cirrhosis and healthy tissue spleen demonstrates that the human FKSG79 or mRNA can be utilized to diagnose of hematological diseases. Additionally the activity of the human FKSG79 can be modulated to treat hematological disorders.

Gastrointestinal and Liver Diseases

Gastrointestinal diseases comprise primary or secondary, acute or chronic diseases of the organs of the gastrointestinal tract which may be acquired or inherited, benign or malignant or metaplastic, and which may affect the organs of the gastrointestinal tract or the body as a whole. They comprise but are not limited to 1) disorders of the esophagus like achalasia, vigorous achalasia, dysphagia, cricopharyngeal incoordination, pre-esophageal dysphagia, diffuse esophageal spasm, globus sensation, Barrett's metaplasia, gastroesophageal reflux, 2) disorders of the stomach and duodenum like functional dyspepsia, inflammation of the gastric mucosa, gastritis, stress gastritis, chronic erosive gastritis, atrophy of gastric glands, metaplasia of gastric tissues, gastric ulcers, duodenal ulcers, neoplasms of the stomach, 3) disorders of the pancreas like acute or chronic pancreatitis, insufficiency of the exocrine or endocrine tissues of the pancreas like steatorrhea, diabetes, neoplasms of the exocrine or endocrine pancreas like 3.1) multiple endocrine neoplasia syndrome, ductal adenocarcinoma, cystadenocarcinoma, islet cell tumors, insulinoma, gastrinoma, carcinoid tumors, glucagonoma, Zollinger-Ellison syndrome, Vipoma syndrome, malabsorption syndrome, 4) disorders of the bowel like chronic inflammatory diseases of the bowel, Crohn's disease, ileus, diarrhea and constipation, colonic inertia, megacolon, malabsorption syndrome, ulcerative colitis, 4.1) functional bowel disorders like irritable bowel syndrome, 4.2) neoplasms of the bowel like familial polyposis, adenocarcinoma, primary malignant lymphoma, carcinoid tumors, Kaposi's sarcoma, polyps, cancer of the colon and rectum.

Liver diseases comprise primary or secondary, acute or chronic diseases or injury of the liver which may be acquired or inherited, benign or malignant, and which may affect the liver or the body as a whole. They comprise but are not limited to disorders of the bilirubin metabolism, jaundice, syndroms of Gilbert's, Crigler-Najjar, Dubin-Johnson and Rotor; intrahepatic cholestasis, hepatomegaly, portal hypertension, ascites, Budd-Chiari syndrome, portal-systemic

encephalopathy, fatty liver, steatosis, Reye's syndrome, liver diseases due to alcohol, alcoholic hepatitis or cirrhosis, fibrosis and cirrhosis, fibrosis and cirrhosis of the liver due to inborn errors of metabolism or exogenous substances, storage diseases, syndromes of Gaucher's, Zellweger's, Wilson's - disease, acute or chronic hepatitis, viral hepatitis and its variants, inflammatory conditions of the liver due to viruses, bacteria, fungi, protozoa, helminths; drug induced disorders of the liver, chronic liver diseases like primary sclerosing cholangitis, alpha₁-antitrypsin-deficiency, primary biliary cirrhosis, postoperative liver disorders like postoperative intrahepatic cholestasis, hepatic granulomas, vascular liver disorders associated with systemic disease, benign or malignant neoplasms of the liver, disturbance of liver metabolism in the new-born or prematurely born.

The human FKSG79 is highly expressed in the following tissues of the gastroenterological system: esophagus tumor, stomach, stomach tumor, colon, colon tumor, small intestine, ileum, ileum tumor, ileum chronic inflammation, rectum, rectum tumor, fetal liver, liver, liver liver cirrhosis, liver lupus disease, liver tumor. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue ileum chronic inflammation and healthy tissue , between diseased tissue liver liver cirrhosis and healthy tissue liver, between diseased tissue liver lupus disease and healthy tissue liver demonstrates that the human FKSG79 or mRNA can be utilized to diagnose of gastroenterological disorders. Additionally the activity of the human FKSG79 can be modulated to treat gastroenterological disorders.

20 *Dermatologic Disorders*

The skin serves several functions. It's an multi-layered organ system that builds an effective protective cover and regulates body temperature, senses painful and pleasant stimuli, keeps substances from entering the body, and provides a shield from the sun's harmful effects. Skin color, texture, and folds help mark people as individuals. Thus, skin disorders or diseases often have important consequences for physical and mental health. Skin disorders include, but are not limited to the conditions described in the following.

Itching (pruritus) is a sensation that instinctively demands scratching, which may be caused by a skin condition or a systemic diseases.

Superficial Skin Disorders affect the uppermost layer of the skin, the stratum corneum or the keratin layer, and it consists of many layers of flattened, dead cells and acts as a barrier to protect the underlying tissue from injury and infection. Disorders of the superficial skin layers involve the stratum corneum and deeper layers of the epidermis.

Examples of superficial skin disorders are provided in the following.

5 Dry skin often occurs in people past middle age, severe dry skin (ichthyosis) results from an inherited scaling disease, such as ichthyosis vulgaris or epidermolytic hyperkeratosis. Ichthyosis also results from nonhereditary disorders, such as leprosy, underactive thyroid, lymphoma, AIDS, and sarcoidosis.

Keratosis pilaris is a common disorder in which dead cells shed from the upper layer of skin and form plugs that fill the openings of hair follicles.

A callus is an area on the stratum corneum or keratin layer, that becomes abnormally thick in response to repeated rubbing.

10 A corn is a pea-sized, thickened area of keratin that occurs on the feet.

Psoriasis is a chronic, recurring disease recognizable by silvery scaling bumps and various-sized plaques (raised patches). An abnormally high rate of growth and turnover of skin cells causes the scaling.

15 Pityriasis rosea is a mild disease that causes scaly, rose-colored, inflamed skin. Pityriasis rosea is possibly caused by an infectious agent, although none has been identified.

Lichen planus, a recurring itchy disease, starts as a rash of small discrete bumps that then combine and become rough, scaly plaques (raised patches).

Dermatitis (eczema) is an inflammation of the upper layers of the skin, causing blisters, redness, swelling, oozing, scabbing, scaling, and usually itching.

20 Forms of dermatitis are contact dermatitis, or chronic dermatitis of the hands and feet, e.g. Pompholyx.

Further examples of dermatitic disorders are atopic dermatitis, seborrheic dermatitis, nummular dermatitis, generalized exfoliative dermatitis, stasis dermatitis, or localized scratch dermatitis (lichen simplex chronicus, neurodermatitis).

25 Other skin disorders are caused by inflammation. The skin can break out in a variety of rashes, sores, and blisters. Some skin eruptions can even be life threatening.

Drug rashes are side effects of medications, mainly allergic reactions to medications.

Toxic epidermal necrolysis is a life-threatening skin disease in which the top layer of the skin peels off in sheets. This condition can be caused by a reaction to a drug, or by some other serious disease.

5 Erythema multiforme, often caused by herpes simplex is a disorder characterized by patches of red, raised skin that often look like targets and usually are distributed symmetrically over the body.

Erythema nodosum is an inflammatory disorder that produces tender red bumps (nodules) under the skin, most often over the shins but occasionally on the arms and other areas.

Granuloma annulare is a chronic skin condition of unknown cause in which small, firm, raised bumps form a ring with normal or slightly sunken skin in the center.

10 Some skin disorders are characterized as blistering diseases. Three autoimmune diseases-- pemphigus, bullous pemphigoid, and dermatitis herpetiformis--are among the most serious.

Pemphigus is an uncommon, sometimes fatal, disease in which blisters (bullae) of varying sizes break out on the skin, the lining of the mouth, and other mucous membranes.

Bullous pemphigoid is an autoimmune disease that causes blistering.

15 Dermatitis herpetiformis is an autoimmune disease in which clusters of intensely itchy, small blisters and hive-like swellings break out and persist. In people with the disease, proteins in wheat, rye, barley, and oat products activate the immune system, which attacks parts of the skin and somehow causes the rash and itching.

Sweating disorders also belong to skin disorders.

20 Prickly heat is an itchy skin rash caused by trapped sweat.

Excessive sweating (hyperhidrosis) may affect the entire surface of the skin, but often it's limited to the palms, soles, armpits, or groin. The affected area is often pink or bluish white, and in severe cases the skin may be cracked, scaly, and soft, especially on the feet.

25 Skin disorders can affect the sebaceous glands. The sebaceous glands, which secrete oil onto the skin, lie in the dermis, the skin layer just below the surface layer (epidermis). Sebaceous gland disorders include acne, rosacea, perioral dermatitis, and sebaceous cysts.

Acne is a common skin condition in which the skin pores become clogged, leading to pimples and inflamed, infected abscesses (collections of pus). Acne tends to develop in teenagers.

Acne is further subdivided in superficial acne or deep acne.

Rosacea is a persistent skin disorder that produces redness, tiny pimples, and broken blood vessels, usually on the central area of the face.

Perioral dermatitis is a red, often bumpy rash around the mouth and on the chin.

- 5 A sebaceous cyst (keratinous cyst) is a slow-growing bump containing dead skin, skin excretions, and other skin particles. These cysts may be small and can appear anywhere.

Hair Disorders also are skin disorders. Hair disorders include excessive hairiness, baldness, and ingrown beard hairs.

- 10 The skin can be infected by bacteria. Bacterial skin infections can range in seriousness from minor acne to a life-threatening condition, such as staphylococcal scalded skin syndrome. The most common bacterial skin infections are caused by Staphylococcus and Streptococcus. Risk factors for skin infections are for example diabetes, AIDS or skin lesions.

Impetigo is a skin infection, caused by Staphylococcus or Streptococcus, leading to the formation of small pus-filled blisters (pustules).

- 15 Folliculitis is an inflammation of the hair follicles caused by infection with Staphylococcus. The infection damages the hairs, which can be easily pulled out.

Boils (furuncles) are large, tender, swollen, raised areas caused by staphylococcal infection around hair follicles.

- 20 Carbuncles are clusters of boils that result in extensive sloughing of skin and scar formation. Carbuncles develop and heal more slowly than single boils and may lead to fever and fatigue.

Erysipelas is a skin infection caused by Streptococcus. A shiny, red, slightly swollen, tender rash develops, often with small blisters. Lymph nodes around the infected area may become enlarged and painful.

- 25 Cellulitis is a spreading infection in, and sometimes beneath, the deep layers of the skin. Cellulitis most often results from a streptococcal infection or a staphylococcal infection. However, many other bacteria can also cause cellulitis.

Paronychia is an infection around the edge of a fingernail or toenail. Paronychia can be caused by many different bacteria, including Pseudomonas and Proteus, and by fungi, such as Candida.

Staphylococcal scalded skin syndrome is a widespread skin infection that can lead to toxic shock syndrome, in which the skin peels off as though burned. Certain types of staphylococci produce a toxic substance that causes the top layer of skin (epidermis) to split from the rest of the skin.

Erythrasma is an infection of the top layers of the skin by the bacterium *Corynebacterium minutissimum*.

Skin infections are often caused by fungi. Fungi that infect the skin (dermatophytes) live only in the dead, topmost layer (stratum corneum) and don't penetrate deeper. Some fungal infections cause no symptoms or produce only a small amount of irritation, scaling, and redness. Other fungal infections cause itching, swelling, blisters, and severe scaling.

Ringworm is a fungal skin infection caused by several different fungi and generally classified by its location on the body.

Examples are Athlete's foot (foot ringworm, caused by either *Trichophyton* or *Epidermophyton*), jock itch (groin ringworm, can be caused by a variety of fungi and yeasts), scalp ringworm, caused by *Trichophyton* or *Microsporum*), nail ringworm and body ringworm (caused by *Trichophyton*).

Candidiasis (yeast infection, moniliasis) is an infection by the yeast *Candida*. *Candida* usually infects the skin and mucous membranes, such as the lining of the mouth and vagina. Rarely, it invades deeper tissues as well as the blood, causing life-threatening systemic candidiasis. The following types of candida infections can be distinguished: Infections in skinfolds (intertriginous infections), vaginal and penile candida infections (vulvovaginitis), thrush, *Perleche* (candida infection at the corners of the mouth), candidal paronychia (candida growing in the nail beds, produces painful swelling and pus).

Tinea versicolor is a fungal infection that causes white to light brown patches on the skin.

The skin can also be affected by parasites, mainly tiny insects or worms.

Scabies is a mite infestation that produces tiny reddish pimples and severe itching. Scabies is caused by the itch mite *Sarcoptes scabiei*.

Lice infestation (pediculosis) causes intense itching and can affect almost any area of the skin. Head lice and pubic lice are two different species.

Creeping eruption (*cutaneous larva migrans*) is a hookworm infection transmitted from warm, moist soil to exposed skin. The infection is caused by a hookworm that normally inhabits dogs and cats.

Many types of viruses invade the skin. The medically important ones cause warts and cold sores (fever blisters) on the lip. Warts are caused by the papillomavirus, and cold sores are caused by the herpes simplex virus. Another important group of viruses that infect the skin belongs to the poxvirus family. Chickenpox remains a common childhood infection. A poxvirus also causes molluscum contagiosum, which is an infection of the skin by a poxvirus that causes skin-colored, smooth, waxy bumps.

Sunlight can cause severe skin damage. Sunburn results from an overexposure to ultraviolet B (UVB) rays. Some sunburned people develop a fever, chills, and weakness, and those with very bad sunburns even may go into shock--low blood pressure, and fainting.

People who are in the sun a lot have an increased risk of skin cancers, including squamous cell carcinoma, basal cell carcinoma, and to some degree, malignant melanoma.

Drugs, among other causes, can cause skin photosensitivity reactions which can occur after only a few minutes of sun exposure. These reactions include redness, peeling, hives, blisters, and thickened, scaling patches (photosensitivity).

Some skin disorders are characterized as Pigment Disorders.

Albinism is a rare, inherited disorder in which no melanin is formed.

Vitiligo is a condition in which a loss of melanocytes results in smooth, whitish patches of skin, which may occur after unusual physical trauma and tends to occur with certain other diseases, including Addison's disease, diabetes, pernicious anemia, and thyroid disease.

Tinea versicolor is a fungal infection of the skin that sometimes results in hyperpigmentation.

Melasma appears on the face (usually the forehead, cheeks, temples, and jaws) as a roughly symmetric group of dark brown patches of pigmentation that are often clearly delineated.

Skin growths, which are abnormal accumulations of different types of cells, may be present at birth or develop later. Noncancerous (benign) growth and cancerous (malignant) growth types are distinguished.

Moles (nevi) are small, usually dark, skin growths that develop from pigment-producing cells in the skin (melanocytes). Most moles are harmless. However, noncancerous moles can develop into malignant melanoma.

Skin tags are soft, small, flesh-colored or slightly darker skin flaps that appear mostly on the neck, in the armpits, or in the groin.

Lipomas are soft deposits of fatty material that grow under the skin, causing round or oval lumps.

5 Angiomas are collections of abnormally dense blood or lymph vessels that are usually located in and below the skin and that cause red or purple discolorations.

Examples of angiomas are port-wine stains, strawberry marks, cavernous hemangiomas, spider angiomas, and lymphangiomas.

Pyogenic granulomas are scarlet, brown, or blue-black slightly raised areas caused by increased growth of capillaries (the smallest blood vessels) and swelling of the surrounding tissue.

10 Seborrheic keratoses (sometimes called seborrheic warts) are flesh-colored, brown, or black growths that can appear anywhere on the skin.

Dermatofibromas are small, red-to-brown bumps (nodules) that result from an accumulation of fibroblasts, the cells that populate the soft tissue under the skin.

15 Keratoacanthomas are round, firm, usually flesh-colored growths that have an unusual central crater containing a pasty material.

Keloids are smooth, shiny, slightly pink, often dome-shaped, proliferative growths of fibrous tissue that form over areas of injury or over surgical wounds.

Skin cancer is the most common form of cancer, but most types of skin cancers are curable.

Basal cell carcinoma is a cancer that originates in the lowest layer of the epidermis.

20 Squamous cell carcinoma is cancer that originates in the middle layer of the epidermis.

Bowen's disease is a form of squamous cell carcinoma that's confined to the epidermis and hasn't yet invaded the underlying dermis.

Melanoma is a cancer that originates in the pigment-producing cells of the skin (melanocytes).

Kaposi's sarcoma is a cancer that originates in the blood vessels, usually of the skin.

25 Paget's disease is a rare type of skin cancer that looks like an inflamed, reddened patch of skin (dermatitis); it originates in glands in or under the skin.

The human FKSG79 is highly expressed in the following dermatological tissues: skin. The expression in the above mentioned tissues demonstrates that the human FKSG79 or mRNA can be utilized to diagnose of dermatological diseases. Additionally the activity of the human FKSG79 can be modulated to treat those diseases.

5 *Musculoskeletal Diseases*

Components of the musculoskeletal system are skeleton, muscles, tendons, ligaments, and other components of joints. Disorders of the musculoskeletal system often cause chronic pain and physical disability. They range from injures, infections, inflammation or other types of disorders. Examples of musculoskeletal disorders are presented in the following.

10 Examples are osteoporosis, postmenopausal osteoporosis, senile osteoporosis, secondary osteoporosis, idiopathic juvenile osteoporosis, Paget's disease of the bone, osteochondromas (osteocartilaginous exostoses), tumors of the bone (benign chondromas, chondroblastomas, chondromyxoid fibromas, osteoid osteomas, giant cell tumors of the bone, multiple myeloma, osteosarcoma (osteogenic sarcoma), fibrosarcomas and malignant fibrous histiocytomas, 15 chondrosarcomas, Ewing's tumor (Ewing's sarcoma), malignant lymphoma of bone (reticulum cell sarcoma, metastatic tumors of the bone), osteoarthritis, and gout and Pseudogout.

Examples of disorders of joints and connective tissue are rheumatoid arthritis, psoriatic arthritis, discoid lupus erythematosus, systemic lupus erythematosus, scleroderma (systemic sclerosis), Sjögren's syndrome, connective tissue disease, polymyositis and dermatomyositis, relapsing 20 polychondritis, vasculitis, polyarteritis nodosa, polymyalgia rheumatica, temporal arteritis, Wegener's granulomatosis, Reiter's syndrome, Behçet's syndrome, ankylosing spondylitis, or Charcot's joints (neuropathic joint disease).

Examples for bone and joint infections are osteomyelitis, and infectious arthritis.

25 Examples of disorders of muscles, bursas, and tendons are spasmodic torticollis, fibromyalgia syndromes (myofascial pain syndromes, fibromyositis), bursitis, tendinitis and tenosynovitis.

Foot problems are, for example ankle sprain, foot fractures, heel spurs, Sever's disease, posterior achilles tendon bursitis, anterior achilles tendon bursitis, posterior tibial neuralgia, pain in the ball of the foot (caused by damage to the nerves between the toes or to the joints between the toes and foot), onychomycosis, or nail discoloration.

30 The human FKSG79 is highly expressed in the following muscle/skeleton tissues: cartilage, adipose, fetal adipose. The expression in muscle/skeleton tissues demonstrates that the

human FKSG79 or mRNA can be utilized to diagnose of diseases of the muscle/skeleton system. Additionally the activity of the human FKSG79 can be modulated to treat those diseases.

Cancer Disorders

Cancer disorders within the scope of this definition comprise any disease of an organ or tissue in mammals characterized by poorly controlled or uncontrolled multiplication of normal or abnormal cells in that tissue and its effect on the body as a whole. Cancer diseases within the scope of the definition comprise benign neoplasms, dysplasias, hyperplasias as well as neoplasms showing metastatic growth or any other transformations like e.g. leukoplakias which often precede a breakout of cancer. Cells and tissues are cancerous when they grow more rapidly than normal cells, displacing or spreading into the surrounding healthy tissue or any other tissues of the body described as metastatic growth, assume abnormal shapes and sizes, show changes in their nucleocytoplasmatic ratio, nuclear polychromasia, and finally may cease. Cancerous cells and tissues may affect the body as a whole when causing paraneoplastic syndromes or if cancer occurs within a vital organ or tissue, normal function will be impaired or halted, with possible fatal results. The ultimate involvement of a vital organ by cancer, either primary or metastatic, may lead to the death of the mammal affected. Cancer tends to spread, and the extent of its spread is usually related to an individual's chances of surviving the disease. Cancers are generally said to be in one of three stages of growth: early, or localized, when a tumor is still confined to the tissue of origin, or primary site; direct extension, where cancer cells from the tumour have invaded adjacent tissue or have spread only to regional lymph nodes; or metastasis, in which cancer cells have migrated to distant parts of the body from the primary site, via the blood or lymph systems, and have established secondary sites of infection. Cancer is said to be malignant because of its tendency to cause death if not treated. Benign tumors usually do not cause death, although they may if they interfere with a normal body function by virtue of their location, size, or paraneoplastic side effects. Hence benign tumors fall under the definition of cancer within the scope of this definition as well. In general, cancer cells divide at a higher rate than do normal cells, but the distinction between the growth of cancerous and normal tissues is not so much the rapidity of cell division in the former as it is the partial or complete loss of growth restraint in cancer cells and their failure to differentiate into a useful, limited tissue of the type that characterizes the functional equilibrium of growth of normal tissue. Cancer tissues may express certain molecular receptors and probably are influenced by the host's susceptibility and immunity and it is known that certain cancers of the breast and prostate, for example, are considered dependent on specific hormones for their existence. The term "cancer" under the scope of the definition is not limited to simple benign neoplasia but comprises any other benign and malign neoplasia like 1) Carcinoma, 2) Sarcoma, 3) Carcinosarcoma, 4) Cancers of the blood-forming tissues, 5) tumors of nerve tissues including the

brain, 6) cancer of skin cells. Cancer according to 1) occurs in epithelial tissues, which cover the outer body (the skin) and line mucous membranes and the inner cavitory structures of organs e.g. such as the breast, lung, the respiratory and gastrointestinal tracts, the endocrine glands, and the genitourinary system. Ductal or glandular elements may persist in epithelial tumors, as in
5 adenocarcinomas like e.g. thyroid adenocarcinoma, gastric adenocarcinoma, uterine adenocarcinoma. Cancers of the pavement-cell epithelium of the skin and of certain mucous membranes, such as e.g. cancers of the tongue, lip, larynx, urinary bladder, uterine cervix, or penis, may be termed epidermoid or squamous-cell carcinomas of the respective tissues and are in the scope of the definition of cancer as well. Cancer according to 2) develops in connective tissues,
10 including fibrous tissues, adipose (fat) tissues, muscle, blood vessels, bone, and cartilage like e.g. osteogenic sarcoma; liposarcoma, fibrosarcoma, synovial sarcoma. Cancer according to 3) is cancer that develops in both epithelial and connective tissue. Cancer disease within the scope of this definition may be primary or secondary, whereby primary indicates that the cancer originated in the tissue where it is found rather than was established as a secondary site through metastasis
15 from another lesion. Cancers and tumor diseases within the scope of this definition may be benign or malign and may affect all anatomical structures of the body of a mammal. By example but not limited to they comprise cancers and tumor diseases of I) the bone marrow and bone marrow derived cells (leukemias), II) the endocrine and exocrine glands like e.g. thyroid, parathyroid, pituitary, adrenal glands, salivary glands, pancreas III) the breast, like e.g. benign or malignant
20 tumors in the mammary glands of either a male or a female, the mammary ducts, adenocarcinoma, medullary carcinoma, comedo carcinoma, Paget's disease of the nipple, inflammatory carcinoma of the young woman, IV) the lung, V) the stomach, VI) the liver and spleen, VII) the small intestine, VIII) the colon, IX) the bone and its supportive and connective tissues like malignant or benign bone tumour, e.g. malignant osteogenic sarcoma, benign osteoma, cartilage tumors; like malignant
25 chondrosarcoma or benign chondroma; bone marrow tumors like malignant myeloma or benign eosinophilic granuloma, as well as metastatic tumors from bone tissues at other locations of the body; X) the mouth, throat, larynx, and the esophagus, XI) the urinary bladder and the internal and external organs and structures of the urogenital system of male and female like ovaries, uterus, cervix of the uterus, testes, and prostate gland, XII) the prostate, XIII) the pancreas, like ductal
30 carcinoma of the pancreas; XIV) the lymphatic tissue like lymphomas and other tumors of lymphoid origin, XV) the skin, XVI) cancers and tumor diseases of all anatomical structures belonging to the respiration and respiratory systems including thoracal muscles and linings, XVII) primary or secondary cancer of the lymph nodes XVIII) the tongue and of the bony structures of the hard palate or sinuses, XXIV) the mouth, cheeks, neck and salivary glands, XX) the blood
35 vessels including the heart and their linings, XXI) the smooth or skeletal muscles and their

ligaments and linings, XXII) the peripheral, the autonomous, the central nervous system including the cerebellum, XXIII) the adipose tissue.

The human FKSG79 is highly expressed in the following cancer tissues: esophagus tumor, stomach tumor, colon tumor, ileum tumor, rectum tumor, liver tumor, Jurkat (T-cells), Raji (B-cells), lung tumor, uterus tumor, ovary tumor, breast tumor, prostate tumor, kidney tumor, HEK 293 cells. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue esophagus tumor and healthy tissue esophagus, between diseased tissue stomach tumor and healthy tissue stomach, between diseased tissue colon tumor and healthy tissue colon, between diseased tissue ileum tumor and healthy tissue , between diseased tissue rectum tumor and healthy tissue rectum, between diseased tissue liver tumor and healthy tissue liver, between diseased tissue Jurkat (T-cells) and healthy tissue T-cells peripheral blood CD4+, between diseased tissue Raji (B-cells) and healthy tissue B-cells peripheral blood CD19+, between diseased tissue lung tumor and healthy tissue lung, between diseased tissue uterus tumor and healthy tissue uterus, between diseased tissue ovary tumor and healthy tissue ovary, between diseased tissue breast tumor and healthy tissue breast, between diseased tissue prostate tumor and healthy tissue prostate, between diseased tissue kidney tumor and healthy tissue kidney, between diseased tissue HEK 293 cells and healthy tissue kidney demonstrates that the human FKSG79 or mRNA can be utilized to diagnose of cancer. Additionally the activity of the human FKSG79 can be modulated to treat cancer.

20 *Inflammatory Diseases*

Inflammatory diseases comprise diseases triggered by cellular or non-cellular mediators of the immune system or tissues causing the inflammation of body tissues and subsequently producing an acute or chronic inflammatory condition. Examples for such inflammatory diseases are hypersensitivity reactions of type I – IV, for example but not limited to hypersensitivity diseases of the lung including asthma, atopic diseases, allergic rhinitis or conjunctivitis, angioedema of the lids, hereditary angioedema, antireceptor hypersensitivity reactions and autoimmune diseases, Hashimoto's thyroiditis, systemic lupus erythematosus, Goodpasture's syndrome, pemphigus, myasthenia gravis, Grave's and Raynaud's disease, type B insulin-resistant diabetes, rheumatoid arthritis, psoriasis, Crohn's disease, scleroderma, mixed connective tissue disease, polymyositis, sarcoidosis, glomerulonephritis, acute or chronic host versus graft reactions.

The human FKSG79 is highly expressed in the following tissues of the immune system and tissues responsive to components of the immune system as well as in the following tissues responsive to mediators of inflammation: ileum chronic inflammation, liver liver cirrhosis, leukocytes (peripheral blood), bone marrow, neutrophils cord blood, neutrophils peripheral blood, spleen liver

cirrhosis. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue ileum chronic inflammation and healthy tissue , between diseased tissue liver liver cirrhosis and healthy tissue liver, between diseased tissue spleen liver cirrhosis and healthy tissue spleen demonstrates that the human FKSG79 or mRNA can be utilized to diagnose of inflammatory diseases. Additionally the activity of the human FKSG79 can be modulated to treat inflammatory diseases.

Disorders Related to Pulmology

Asthma is thought to arise as a result of interactions between multiple genetic and environmental factors and is characterized by three major features: 1) intermittent and reversible airway obstruction caused by bronchoconstriction, increased mucus production, and thickening of the walls of the airways that leads to a narrowing of the airways, 2) airway hyperresponsiveness, and 3) airway inflammation. Certain cells are critical to the inflammatory reaction of asthma and they include T cells and antigen presenting cells, B cells that produce IgE, and mast cells, basophils, eosinophils, and other cells that bind IgE. These effector cells accumulate at the site of allergic reaction in the airways and release toxic products that contribute to the acute pathology and eventually to tissue destruction related to the disorder. Other resident cells, such as smooth muscle cells, lung epithelial cells, mucus-producing cells, and nerve cells may also be abnormal in individuals with asthma and may contribute to its pathology. While the airway obstruction of asthma, presenting clinically as an intermittent wheeze and shortness of breath, is generally the most pressing symptom of the disease requiring immediate treatment, the inflammation and tissue destruction associated with the disease can lead to irreversible changes that eventually make asthma a chronic and disabling disorder requiring long-term management.

Chronic obstructive pulmonary (or airways) disease (COPD) is a condition defined physiologically as airflow obstruction that generally results from a mixture of emphysema and peripheral airway obstruction due to chronic bronchitis [Botstein, 1980]. Emphysema is characterised by destruction of alveolar walls leading to abnormal enlargement of the air spaces of the lung. Chronic bronchitis is defined clinically as the presence of chronic productive cough for three months in each of two successive years. In COPD, airflow obstruction is usually progressive and is only partially reversible. By far the most important risk factor for development of COPD is cigarette smoking, although the disease does also occur in non-smokers.

The human FKSG79 is highly expressed in the following tissues of the respiratory system: leukocytes (peripheral blood), neutrophils cord blood, neutrophils peripheral blood, fetal lung, lung, lung right upper lobe, lung right mid lobe, lung right lower lobe, lung tumor, trachea, primary bronchia. The expression in the above mentioned tissues demonstrates that the human FKSG79 or

mRNA can be utilized to diagnose of respiratory diseases. Additionally the activity of the human FKSG79 can be modulated to treat those diseases.

Disorders Related to Urology

5 Genitourinary disorders comprise benign and malign disorders of the organs constituting the genitourinary system of female and male, renal diseases like acute or chronic renal failure, immunologically mediated renal diseases like renal transplant rejection, lupus nephritis, immune complex renal diseases, glomerulopathies, nephritis, toxic nephropathy, obstructive uropathies like benign prostatic hyperplasia (BPH), neurogenic bladder syndrome, urinary incontinence like urge-, stress-, or overflow incontinence, pelvic pain, and erectile dysfunction.

10 The human FKSG79 is highly expressed in the following urological tissues: prostate, prostate, prostate, prostate BPH, prostate tumor, bladder, bladder, bladder, ureter, corpus cavernosum, fetal kidney, kidney, kidney, kidney tumor, renal epithelial cells, HEK 293 cells. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue prostate BPH and healthy tissue prostate demonstrates that the human FKSG79 or mRNA can be
15 utilized to diagnose of urological disorders. Additionally the activity of the human FKSG79 can be modulated to treat urological disorders.

Metabolic Disorders

20 Metabolic diseases are defined as conditions which result from an abnormality in any of the chemical or biochemical transformations and their regulating systems essential to producing energy, to regenerating cellular constituents, to eliminating unneeded products arising from these processes, and to regulate and maintain homeostasis in a mammal regardless of whether acquired or the result of a genetic transformation. Depending on which metabolic pathway is involved, a single defective transformation or disturbance of its regulation may produce consequences that are narrow, involving a single body function, or broad, affecting many organs, organ-systems or the
25 body as a whole. Diseases resulting from abnormalities related to the fine and coarse mechanisms that affect each individual transformation, its rate and direction or the availability of substrates like amino acids, fatty acids, carbohydrates, minerals, cofactors, hormones, regardless whether they are inborn or acquired, are well within the scope of the definition of a metabolic disease according to this application.

30 Metabolic diseases often are caused by single defects in particular biochemical pathways, defects that are due to the deficient activity of individual enzymes or molecular receptors leading to the regulation of such enzymes. Hence in a broader sense disturbances of the underlying genes, their

products and their regulation lie well within the scope of this definition of a metabolic disease. For example, but not limited to, metabolic diseases may affect 1) biochemical processes and tissues ubiquitous all over the body, 2) the bone, 3) the nervous system, 4) the endocrine system, 5) the muscle including the heart, 6) the skin and nervous tissue, 7) the urogenital system, 8) the homeostasis of body systems like water and electrolytes. For example, but not limited to, metabolic diseases according to 1) comprise obesity, amyloidosis, disturbances of the amino acid metabolism like branched chain disease, hyperaminoacidemia, hyperaminoaciduria, disturbances of the metabolism of urea, hyperammonemia, mucopolysaccharidoses e.g. Maroteaux-Lamy syndrom, storage diseases like glycogen storage diseases and lipid storage diseases, glycogenosis diseases like Cori's disease, malabsorption diseases like intestinal carbohydrate malabsorption, oligosaccharidase deficiency like maltase-, lactase-, sucrase-insufficiency, disorders of the metabolism of fructose, disorders of the metabolism of galactose, galactosaemia, disturbances of carbohydrate utilization like diabetes, hypoglycemia, disturbances of pyruvate metabolism, hypolipidemia, hypolipoproteinemia, hyperlipidemia, hyperlipoproteinemia, carnitine or carnitine acyltransferase deficiency, disturbances of the porphyrin metabolism, porphyrias, disturbances of the purine metabolism, lysosomal diseases, metabolic diseases of nerves and nervous systems like gangliosidoses, sphingolipidoses, sulfatidoses, leucodystrophies, Lesch-Nyhan syndrome. For example, but not limited to, metabolic diseases according to 2) comprise osteoporosis, osteomalacia like osteoporosis, osteopenia, osteogenesis imperfecta, osteopetrosis, osteonecrosis, Paget's disease of bone, hypophosphatemia. For example, but not limited to, metabolic diseases according to 3) comprise cerebellar dysfunction, disturbances of brain metabolism like dementia, Alzheimer's disease, Huntington's chorea, Parkinson's disease, Pick's disease, toxic encephalopathy, demyelinating neuropathies like inflammatory neuropathy, Guillain-Barré syndrome. For example, but not limited to, metabolic diseases according to 4) comprise primary and secondary metabolic disorders associated with hormonal defects like any disorder stemming from either an hyperfunction or hypofunction of some hormone-secreting endocrine gland and any combination thereof. They comprise Sipple's syndrome, pituitary gland dysfunction and its effects on other endocrine glands, such as the thyroid, adrenals, ovaries, and testes, acromegaly, hyper- and hypothyroidism, euthyroid goiter, euthyroid sick syndrome, thyroiditis, and thyroid cancer, over- or underproduction of the adrenal steroid hormones, adrenogenital syndrome, Cushing's syndrome, Addison's disease of the adrenal cortex, Addison's pernicious anemia, primary and secondary aldosteronism, diabetes insipidus, carcinoid syndrome, disturbances caused by the dysfunction of the parathyroid glands, pancreatic islet cell dysfunction, diabetes, disturbances of the endocrine system of the female like estrogen deficiency, resistant ovary syndrome. For example, but not limited to, metabolic diseases according to 5) comprise muscle weakness, myotonia, Duchenne's and other muscular dystrophies, dystrophia myotonica of Steinert,

mitochondrial myopathies like disturbances of the catabolic metabolism in the muscle, carbohydrate and lipid storage myopathies, glycogenoses, myoglobinuria, malignant hyperthermia, polymyalgia rheumatica, dermatomyositis, primary myocardial disease, cardiomyopathy. For example, but not limited to, metabolic diseases according to 6) comprise disorders of the ectoderm, neurofibromatosis, scleroderma and polyarteritis, Louis-Bar syndrome, von Hippel-Lindau disease, Sturge-Weber syndrome, tuberous sclerosis, amyloidosis, porphyria. For example, but not limited to, metabolic diseases according to 7) comprise sexual dysfunction of the male and female. For example, but not limited to, metabolic diseases according to 8) comprise confused states and seizures due to inappropriate secretion of antidiuretic hormone from the pituitary gland, Liddle's syndrome, Bartter's syndrome, Fanconi's syndrome, renal electrolyte wasting, diabetes insipidus.

The human FKSG79 is highly expressed in the following metabolic disease related tissues: fetal liver, liver, liver liver cirrhosis, liver lupus disease, spleen liver cirrhosis, cartilage and adipose. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue liver liver cirrhosis and healthy tissue liver, between diseased tissue liver lupus disease and healthy tissue liver, between diseased tissue spleen liver cirrhosis and healthy tissue spleen demonstrates that the human FKSG79 or mRNA can be utilized to diagnose of metabolic diseases. Additionally the activity of the human FKSG79 can be modulated to treat metabolic diseases.

Infections

Certain bacteria, viruses, fungi and parasites are able to establish an infection of the human body. This invention relates to treatment of infectious diseases. In the following, examples of pathogens potentially leading to infections and infectious diseases are presented. The diseases mentioned serve as examples, the scope of the invention is not limited to infections presented here.

Examples of infections of the skin and underlying tissue are: cellulitis, necrotizing fasciitis, skin gangrene, lymphadenitis, acute lymphangitis, impetigo, skin abscesses, folliculitis, boils (furuncles), erysipelas, carbuncles (clusters of boils and skin abscesses), staphylococcal scalded skin syndrome, erythrasma or paronychia (can be caused by many bacteria and fungi). Most of these are bacterial infections. The most common bacterial skin infections are caused by Staphylococcus and Streptococcus.

Skin infections caused by fungi are ringworm, a fungal skin infection caused by several different fungi and generally classified by its location on the body. Examples are Athlete's foot (foot ringworm, caused by either Trichophyton or Epidermophyton), jock itch (groin ringworm, can be

caused by a variety of fungi and yeasts), scalp ringworm, caused by *Trichophyton* or *Microsporum*), nail ringworm and body ringworm (caused by *Trichophyton*).

5 Candidiasis (yeast infection, moniliasis) is an infection by the yeast *Candida*. The following types of candida infections can be distinguished: Infections in skinfolds (intertriginous infections), vaginal and penile candida infections (vulvovaginitis), thrush, *Perlèche* (candida infection at the corners of the mouth), candidal paronychia (candida growing in the nail beds, produces painful swelling and pus). *Candida* can also lead to generalized systemic infections especially in the immunocompromised host.

Tinea versicolor is a fungal infection that causes white to light brown patches on the skin.

10 The skin can also be affected by parasites, mainly tiny insects or worms. Examples are scabies (mite infestation), lice infestation (pediculosis, head lice and pubic lice are two different species), or creeping eruption (*cutaneous larva migrans*, a hookworm infection).

15 Many types of viruses invade the skin. Examples are papillomaviruses (causing warts), herpes simplex virus (causing e.g. cold sores), or members of the poxvirus family (*molluscum contagiosum* (infection of the skin, causing skin-colored, smooth, waxy bumps).

Abscesses are accumulation of pus, usually caused by a bacterial infection. Examples are abdominal abscesses, head and neck abscesses, muscle abscesses, or hand abscesses.

20 Bacteremia, the presence of bacteria in the bloodstream, is common and usually causes no symptoms. Most bacteria that enter the bloodstream are rapidly removed by white blood cells. Sometimes, however, there are too many bacteria to be removed easily, and an infection called sepsis develops, causing severe symptoms. In some cases, sepsis leads to a life-threatening condition called septic shock.

25 Bacilli are a type of bacteria classified according to their distinctive rod-like shape. Bacteria are either spherical (coccal), rod-like (bacillary), or spiral/helical (spirochetal) in shape. Gram-positive or gram-negative bacilli are distinguished

Examples of gram-positive bacillary infections are erysipelotheicosis (caused by *Erysipelothrix rhusiopathiae*), listeriosis (caused by *Listeria monocytogenes*), and anthrax (caused by *Bacillus anthracis*). Within anthrax, pulmonary anthrax, gastrointestinal anthrax and anthrax skin sores can be distinguished.

30 Examples of gram-negative bacillary infections are *Hemophilus* infections, *Hemophilus influenzae* infections, *Hemophilus ducreyi* (causes chancroid), Brucellosis (undulant, Malta, Mediterranean,

or Gibraltar fever, caused by *Brucella* bacteria), tularemia (rabbit fever, deer fly fever, caused by *Francisella tularensis*), plague (black death, caused by *Yersinia pestis*, bubonic plague, pneumonic plague, septicemic plague and *pestis minor* are distinguished), cat-scratch disease (caused by the bacterium *Bartonella henselae*), *Pseudomonas* infections (especially *Pseudomonas aeruginosa*),
5 infections of the gastrointestinal tract or blood caused by *Campylobacter* bacteria (e.g. *Campylobacter pylori* [*Helicobacter pylori*]), cholera (infection of the small intestine caused by *Vibrio cholerae*), infections with other *Vibrio* spp., *Enterobacteriaceae* infections (cause e.g. infections of the gastrointestinal tract, members of the group are *Salmonella*, *Shigella*, *Escherichia*, *Klebsiella*, *Enterobacter*, *Serratia*, *Proteus*, *Morganella*, *Providencia*, and *Yersinia*), *Klebsella*
10 pneumonia infections (severe lung infection), typhoid fever (caused by *Salmonella typhi*), nontyphoidal *Salmonella* infections, or Shigellosis (bacillary dysentery, an intestinal infection caused by *Shigella* bacteria).

Bacteria that have a spherical shape are called cocci. Cocci that can cause infection in humans include staphylococci, streptococci (group A streptococci, group B streptococci, groups C and G
15 streptococci, group D streptococci and enterococci), pneumococci (cause e.g. pneumonia, thoracic empyema, bacterial meningitis, bacteremia, pneumococcal endocarditis, peritonitis, pneumococcal arthritis or otitis media), and meningococci. Toxic shock syndrome is an infection usually caused by staphylococci, which may rapidly worsen to severe, untreatable shock. Meningococci (*Neisseria meningitidis*) may cause infection of the layers covering the brain and spinal cord (meningitis).
20 *Neisseria gonorrhoeae* cause gonorrhoea, a sexually transmitted disease.

Spirochetal Infections are infections with spirochetes, corkscrew-shaped bacteria. Examples include infections with *Treponema*, *Borrelia*, *Leptospira*, and *Spirillum*.

Treponematoses (e.g. yaws, pinta) are caused by a spirochete that is indistinguishable from *Treponema pallidum* (causes syphilis).

25 Relapsing fever (tick fever, recurrent fever, or famine fever) is a disease caused by several strains of *Borrelia* bacteria.

Lyme disease (transmitted by deer ticks) is caused by the spirochete *Borrelia burgdorferi*.

Other examples for infections with spirochetes are Leptospirosis (a group of infections including Weil's syndrome, infectious (spirochetal) jaundice, and canicola fever), or rat-bite fever).

30 Disease-causing anaerobic bacteria include clostridia, peptococci, and peptostreptococci. Other examples are *Bacteroides fragilis*, *Prevotella melaninogenica* and *Fusobacterium*. Infections with anaerobic bacteria include dental abscesses, jawbone infections, periodontal disease, chronic

sinusitis and middle ear infection, and abscesses in the brain, spinal cord, lung, abdominal cavity, liver, uterus, genitals, skin, and blood vessels. Examples for Clostridial infections tetanus (lockjaw, caused by the bacterium *Clostridium tetani*), or Actinomycosis (a chronic infection caused mainly by *Actinomyces israelii*).

5 Tuberculosis and leprosy are caused by Mycobacteria. Tuberculosis is caused by the airborne bacterium *Mycobacterium tuberculosis*, *M. bovis*, or *M. africanum*. Leprosy (Hansen's disease) is caused by the bacterium *Mycobacterium leprae*.

Rickettsial infections are also known. Examples of diseases caused by Rickettsiae or Ehrlichiae are murine typhus (caused by *Rickettsia typhi*), Rocky Mountain spotted fever (caused by *Rickettsia rickettsii*), epidemic typhus (*Rickettsia prowazekii*), scrub typhus (*Rickettsia tsutsugamushi*), Ehrlichiosis (*Ehrlichia canis* or closely related species), Rickettsial-pox, (Rickettsia akari), Q fever (*Coxiella burnetii*), or trench fever (*Bartonella quintana*).

A parasite is an organism, such as a single-celled animal (protozoan) or worm, that survives by living inside another, usually much larger, organism. Examples for parasitic infections are Amebiasis (caused by *Entamoeba histolytica*), Giardiasis (*Giardia lamblia*), Malaria (*Plasmodium*), Toxoplasmosis (*Toxoplasma gondii*), Babesiosis (*Babesia* parasites), Trichuriasis (*Trichuris trichiura*, an intestinal roundworm), Ascariasis (*Ascaris lumbricoides*), Hookworm Infection (*Ancylostoma duodenale* or *Necator americanus*), Trichinosis (*Trichinella spiralis*), Toxocariasis (visceral larva migrans, caused by the invasion of organs by roundworm larvae, such as *Toxocara canis* and *Toxocara cati*), Pork tapeworm infection (*Taenia solium*), or Fish tapeworm infection (*Diphyllobothrium latum*).

Fungi tend to cause infections in people with a compromised immune system. Examples for fungal infections are Histoplasmosis (caused by *Histoplasma capsulatum*), Coccidioidomycosis (*Coccidioides immitis*), Blastomycosis (*Blastomyces dermatitidis*), Candidiasis (caused by strains of *Candida*, especially *Candida albicans*), or Sporotrichosis (*Sporothrix schenckii*).

Viral infections represent a very common type of infection. A virus is a small infectious particle that needs a living cell reproduce. Examples of viral infections are given in the following. Respiratory viral infections are, for example, common cold (caused by Picornaviruses [e.g. rhinoviruses], Influenza viruses or respiratory syncytial viruses), Influenza (caused by influenza A or influenza B virus), Herpesvirus Infections (herpes simplex, herpes zoster, Epstein-Barr virus, cytomegalovirus, herpesvirus 6, human herpesvirus 7, or herpesvirus 8 (cause of Kaposi's sarcoma in people with AIDS), central nervous system viral infections (e.g. Rabies, Creutzfeldt-Jakob disease (subacute spongiform encephalopathy), progressive multifocal leukoencephalopathy (rare

manifestation of polyomavirus infection of the brain caused by the JC virus), Tropical spastic paraparesis (HTLV-I), Arbovirus infections (e.g. Arbovirus encephalitis, yellow fever, or dengue fever), Arenavirus Infections (e.g. Lymphocytic choriomeningitis), hemorrhagic fevers (e.g. Bolivian and Argentinean hemorrhagic fever and Lassa fever, Hantavirus infection, Ebola and Marburg viruses).

Human immunodeficiency virus (HIV) infection is an infection caused by HIV-1 or HIV-II virus. The infection results in progressive destruction of lymphocytes. This leads to acquired immunodeficiency syndrome (AIDS).

Examples of typical infections of people with an impaired immune system (opportunistic infections) are including but are not limited to nocardiosis (caused by *Nocardia asteroides*), aspergillosis, mucormycosis, and cytomegalovirus infection.

Examples for sexually transmitted (venereal) diseases are syphilis (caused by *Treponema pallidum*), gonorrhea (*Neisseria gonorrhoeae*), chancroid (*Hemophilus ducreyi*), lymphogranuloma venereum (*Chlamydia trachomatis*), granuloma inguinale (*Calymmatobacterium granulomatis*), nongonococcal urethritis and chlamydial cervicitis (caused by *Chlamydia trachomatis*, *Ureaplasma urealyticum*, *Trichomonas vaginalis* or herpes simplex virus), trichomoniasis (*Trichomonas vaginalis*), genital candidiasis, genital herpes, genital warts (caused by papillomaviruses), or HIV infection.

The human FKSG79 is highly expressed in the following antiinfective tissues: T-cells peripheral blood CD4+, T-cells peripheral blood CD4+, T-cells peripheral blood CD4+ D117 II virus infected, T-cells peripheral blood CD4+ D34 virus infected. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue T-cells peripheral blood CD4+ D117 II virus infected and healthy tissue T-cells peripheral blood CD4+, between diseased tissue T-cells peripheral blood CD4+ D34 virus infected and healthy tissue T-cells peripheral blood CD4+ demonstrates that the human FKSG79 or mRNA can be utilized to diagnose of infective diseases. Additionally the activity of the human FKSG79 can be modulated to treat infective diseases.

Applications

The present invention provides for both prophylactic and therapeutic methods for cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases.

The regulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of FKSG79. An agent that modulates activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of the polypeptide, a peptide, a peptidomimetic, or any small molecule. In one embodiment, the agent stimulates one or more of the biological activities of FKSG79. Examples of such stimulatory agents include the active FKSG79 and nucleic acid molecules encoding a portion of FKSG79. In another embodiment, the agent inhibits one or more of the biological activities of FKSG79. Examples of such inhibitory agents include antisense nucleic acid molecules and antibodies. These regulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g. by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by unwanted expression or activity of FKSG79 or a protein in the FKSG79 signaling pathway. In one embodiment, the method involves administering an agent like any agent identified or being identifiable by a screening assay as described herein, or combination of such agents that modulate say upregulate or downregulate the expression or activity of FKSG79 or of any protein in the FKSG79 signaling pathway. In another embodiment, the method involves administering a regulator of FKSG79 as therapy to compensate for reduced or undesirably low expression or activity of FKSG79 or a protein in the FKSG79 signaling pathway.

Stimulation of activity or expression of FKSG79 is desirable in situations in which activity or expression is abnormally low and in which increased activity is likely to have a beneficial effect. Conversely, inhibition of activity or expression of FKSG79 is desirable in situations in which activity or expression of FKSG79 is abnormally high and in which decreasing its activity is likely to have a beneficial effect.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby incorporated by reference.

Pharmaceutical Compositions

This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

The nucleic acid molecules, polypeptides, and antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharma-

5 ceutically acceptable carrier“ is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

10 The invention includes pharmaceutical compositions comprising a regulator of FKSG79 expression or activity (and/or a regulator of the activity or expression of a protein in the FKSG79 signaling pathway) as well as methods for preparing such compositions by combining one or more such regulators and a pharmaceutically acceptable carrier. Also within the invention are pharmaceutical compositions comprising a regulator identified using the screening assays of the invention packaged with instructions for use. For regulators that are antagonists of FKSG79 activity or which reduce FKSG79 expression, the instructions would specify use of the pharmaceutical composition for treatment of cardiovascular diseases, infections, dermatological diseases, 15 gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases. For regulators that are agonists of FKSG79 activity or increase FKSG79 expression, the instructions would specify use of the pharmaceutical composition for treatment of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic 20 diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases.

25 An antagonist of FKSG79 may be produced using methods which are generally known in the art. In particular, purified FKSG79 may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind FKSG79. Antibodies to FKSG79 may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies like those which inhibit dimer formation are especially preferred for therapeutic use.

30 In another embodiment of the invention, the polynucleotides encoding FKSG79, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding FKSG79 may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding FKSG79. Thus, complementary molecules or fragments may be used to modulate FKSG79 activity, or to achieve regulation of gene function.

Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding FKSG79.

5 Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors which will express nucleic acid sequence complementary to the polynucleotides of the gene encoding FKSG79. These techniques are described, for example, in [Scott and Smith (1990) *Science* 249:386-390].

10 Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical composition containing FKSG79 in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of FKSG79, antibodies to FKSG79, and mimetics, agonists, antagonists, or inhibitors of FKSG79. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. 15 The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones. 20

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. 25 30

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EMTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a pharmaceutically acceptable polyol like glycerol, propylene glycol, liquid polyethylene glycol, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin. Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a polypeptide or antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.

Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum

tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

- 5 For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the
10 formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

- 15 The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation,
20 including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted
25 to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to
30 physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique

characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration. For pharmaceutical compositions which include an antagonist of FKSG79 activity, a compound which reduces expression of FKSG79, or a compound which reduces expression or activity of a protein in the FKSG79 signaling pathway or any combination thereof, the instructions for administration will specify use of the composition for cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases. For pharmaceutical compositions which include an agonist of FKSG79 activity, a compound which increases expression of FKSG79, or a compound which increases expression or activity of a protein in the FKSG79 signaling pathway or any combination thereof, the instructions for administration will specify use of the composition for cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases.

Diagnostics

In another embodiment, antibodies which specifically bind FKSG79 may be used for the diagnosis of disorders characterized by the expression of FKSG79, or in assays to monitor patients being treated with FKSG79 or agonists, antagonists, and inhibitors of FKSG79. Antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for FKSG79 include methods which utilize the antibody and a label to detect FKSG79 in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent joining with a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring FKSG79, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of FKSG79 expression. Normal or standard values for FKSG79 expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to FKSG79 under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, preferably by photometric means. Quantities of FKSG79

expressed in subject samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding FKSG79 may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of FKSG79 may be correlated with disease. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of FKSG79, and to monitor regulation of FKSG79 levels during therapeutic intervention.

Polynucleotide sequences encoding FKSG79 may be used for the diagnosis of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases associated with expression of FKSG79. The polynucleotide sequences encoding FKSG79 may be used in Southern, Northern, or dot-blot analysis, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and ELISA assays; and in microarrays utilizing fluids or tissues from patient biopsies to detect altered FKSG79 expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding FKSG79 may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding FKSG79 may be labelled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered from that of a comparable control sample, the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding FKSG79 in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases associated with expression of FKSG79, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding

FKSG79, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from
5 patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, large numbers of different small test compounds
10 are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with FKSG79, or fragments thereof, and washed. Bound FKSG79 is then detected by methods well known in the art. Purified FKSG79 can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

15 In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding FKSG79 specifically compete with a test compound for binding FKSG79. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with FKSG79.

G-protein coupled receptors are ubiquitous in the mammalian host and are responsible for many
20 biological functions, including many pathologies. Accordingly, it is desirable to find compounds and drugs which stimulate a G-protein coupled receptor on the one hand and which can inhibit the function of a G-protein coupled receptor on the other hand. For example, compounds which activate the G-protein coupled receptor may be employed for therapeutic purposes, such as the treatment of asthma, Parkinson's disease, acute heart failure, urinary retention, and osteoporosis.

25 In particular, compounds which activate the receptors of the present invention are useful in treating various cardiovascular ailments such as caused by the lack of pulmonary blood flow or hypertension. In addition these compounds may also be used in treating various physiological disorders relating to abnormal control of fluid and electrolyte homeostasis and in diseases associated with abnormal angiotensin-induced aldosterone secretion.

30 In general, compounds which inhibit activation of the G-protein coupled receptor may be employed for a variety of therapeutic purposes, for example, for the treatment of hypotension and/or hypertension, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders including schizophrenia, manic excitement, depression, delirium, dementia or severe mental retardation, dyskinesias, such as

Huntington's disease or Tourett's syndrome, among others. Compounds which inhibit G-protein coupled receptors have also been useful in reversing endogenous anorexia and in the control of bulimia.

Determination of a Therapeutically Effective Dose

5 The determination of a therapeutically effective dose is well within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient which increases or decreases FKSG79 activity relative to FKSG79 activity which occurs in the absence of the therapeutically effective dose. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or
10 pigs. The animal model also can be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

Therapeutic efficacy and toxicity, e.g., ED₅₀ (the dose therapeutically effective in 50% of the population) and LD₅₀ (the dose lethal to 50% of the population), can be determined by standard
15 pharmaceutical procedures in cell cultures or experimental animals. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD₅₀/ED₅₀. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating
20 concentrations that include the ED₅₀ with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration. The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active ingredient or to maintain the desired effect. Factors which can be taken into
25 account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation.

30 Normal dosage amounts can vary from 0.1 micrograms to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular

cells, conditions, locations, etc. If the reagent is a single-chain antibody, polynucleotides encoding the antibody can be constructed and introduced into a cell either *ex vivo* or *in vivo* using well-established techniques including, but not limited to, transferrin-polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, "gene gun", and DEAE- or calcium phosphate-mediated transfection.

If the expression product is mRNA, the reagent is preferably an antisense oligonucleotide or a ribozyme. Polynucleotides which express antisense oligonucleotides or ribozymes can be introduced into cells by a variety of methods, as described above. Preferably, a reagent reduces expression of FKSG79 gene or the activity of FKSG79 by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the reagent. The effectiveness of the mechanism chosen to decrease the level of expression of FKSG79 gene or the activity of FKSG79 can be assessed using methods well known in the art, such as hybridization of nucleotide probes to FKSG79-specific mRNA, quantitative RT-PCR, immunologic detection of FKSG79, or measurement of FKSG79 activity.

In any of the embodiments described above, any of the pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents can act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects. Any of the therapeutic methods described above can be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

Nucleic acid molecules of the invention are those nucleic acid molecules which are contained in a group of nucleic acid molecules consisting of (i) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, (ii) nucleic acid molecules comprising the sequence of SEQ ID NO: 1, (iii) nucleic acid molecules having the sequence of SEQ ID NO: 1, (iv) nucleic acid molecules the complementary strand of which hybridizes under stringent conditions to a nucleic acid molecule of (i), (ii), or (iii); and (v) nucleic acid molecules the sequence of which differs from the sequence of a nucleic acid molecule of (iii) due to the degeneracy of the genetic code, wherein the polypeptide encoded by said nucleic acid molecule has FKSG79 activity.

Polypeptides of the invention are those polypeptides which are contained in a group of polypeptides consisting of (i) polypeptides having the sequence of SEQ ID NO: 2, (ii) polypeptides comprising the sequence of SEQ ID NO: 2, (iii) polypeptides encoded by nucleic acid molecules of the invention and (iv) polypeptides which show at least 99%, 98%, 95%, 90%, or 80% homology with a polypeptide of (i), (ii), or (iii), wherein said purified polypeptide has FKSG79 activity.

An object of the invention is a method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising the steps of (i) contacting a test compound with a FKSG79 polypeptide, (ii) detect binding of said test compound to said FKSG79 polypeptide. E.g., compounds that bind to the FKSG79 polypeptide are identified potential therapeutic agents for such a disease.

Another object of the invention is a method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising the steps of (i) determining the activity of a FKSG79 polypeptide at a certain concentration of a test compound or in the absence of said test compound, (ii) determining the activity of said polypeptide at a different concentration of said test compound. E.g., compounds that lead to a difference in the activity of the FKSG79 polypeptide in (i) and (ii) are identified potential therapeutic agents for such a disease.

Another object of the invention is a method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising the steps of (i) determining the activity of a FKSG79 polypeptide at a certain concentration of a test compound, (ii) determining the activity of a FKSG79 polypeptide at the presence of a compound known to be a regulator of a FKSG79 polypeptide. E.g., compounds that show similar effects on the activity of the FKSG79 polypeptide in (i) as compared to compounds used in (ii) are identified potential therapeutic agents for such a disease.

Other objects of the invention are methods of the above, wherein the step of contacting is in or at the surface of a cell.

Other objects of the invention are methods of the above, wherein the cell is in vitro.

Other objects of the invention are methods of the above, wherein the step of contacting is in a cell-free system.

5 Other objects of the invention are methods of the above, wherein the polypeptide is coupled to a detectable label.

Other objects of the invention are methods of the above, wherein the compound is coupled to a detectable label.

Other objects of the invention are methods of the above, wherein the test compound displaces a ligand which is first bound to the polypeptide.

10 Other objects of the invention are methods of the above, wherein the polypeptide is attached to a solid support.

Other objects of the invention are methods of the above, wherein the compound is attached to a solid support.

15 Another object of the invention is a method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising the steps of (i) contacting a test compound with a FKSG79 polynucleotide, (ii) detect binding of said test compound to said
20 FKSG79 polynucleotide. Compounds that, e.g., bind to the FKSG79 polynucleotide are potential therapeutic agents for the treatment of such diseases.

Another object of the invention is the method of the above, wherein the nucleic acid molecule is RNA.

25 Another object of the invention is a method of the above, wherein the contacting step is in or at the surface of a cell.

Another object of the invention is a method of the above, wherein the contacting step is in a cell-free system.

Another object of the invention is a method of the above, wherein the polynucleotide is coupled to a detectable label.

Another object of the invention is a method of the above, wherein the test compound is coupled to a detectable label.

Another object of the invention is a method of diagnosing a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising the steps of (i) determining the amount of a FKSG79 polynucleotide in a sample taken from said mammal, (ii) determining the amount of FKSG79 polynucleotide in healthy and/or diseased mammal. A disease is diagnosed, e.g., if there is a substantial similarity in the amount of FKSG79 polynucleotide in said test mammal as compared to a diseased mammal.

Another object of the invention is a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising a therapeutic agent which binds to a FKSG79 polypeptide.

Another object of the invention is a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising a therapeutic agent which regulates the activity of a FKSG79 polypeptide.

Another object of the invention is a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising a therapeutic agent which regulates the activity of a FKSG79 polypeptide, wherein said therapeutic agent is (i) a small molecule, (ii) an RNA molecule, (iii) an antisense oligonucleotide, (iv) a polypeptide, (v) an antibody, or (vi) a ribozyme.

Another object of the invention is a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising a FKSG79 polynucleotide.

Another object of the invention is a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising a FKSG79 polypeptide.

Another object of the invention is the use of regulators of a FKSG79 for the preparation of a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal.

Another object of the invention is a method for the preparation of a pharmaceutical composition useful for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising the steps of (i) identifying a regulator of FKSG79, (ii) determining whether said regulator ameliorates the symptoms of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal; and (iii) combining of said regulator with an acceptable pharmaceutical carrier.

Another object of the invention is the use of a regulator of FKSG79 for the regulation of FKSG79 activity in a mammal having a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases.

The uses, methods or compositions of the invention are useful for each single disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases.

The expression of human FKSG79 in inflammation and hematological related tissues (as described above) suggests a particular – but not limited to – utilization of FKSG79 for diagnosis and modulation of hematological diseases and inflammation. Furthermore the above described

expression suggest a – but not limited to – utilization of FKSG79 to cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases.

- 5 The examples below are provided to illustrate the subject invention. These examples are provided by way of illustration and are not included for the purpose of limiting the invention.

Examples

Example 1: Search for homologous sequences in public sequence data bases

The degree of homology can readily be calculated by known methods. Preferred methods to determine homology are designed to give the largest match between the sequences tested. Methods to determine homology are codified in publicly available computer programs such as BestFit, BLASTP, BLASTN, and FASTA. The BLAST programs are publicly available from NCBI and other sources in the internet.

For FKSG79 the following hits to known sequences were identified by using the BLAST algorithm [Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ; Nucleic Acids Res 1997 Sep 1; 25(17): 3389-402] and the following set of parameters: matrix = BLOSUM62 and low complexity filter. The following databases were searched: NCBI (non-redundant database) and DERWENT patent database (Geneseq).

The following hits were found:

- >emb|AL590222.4| Human DNA sequence from clone RP11-159L8 on chromosome Xq13.2-21.2
15 Contains the gene for a putative purinergic receptor (FKSG79), complete sequence
Length = 166810, Score = 2419 bits (1258), Expect = 0.0, Identities = 1258/1258 (100%)
- >ref|NM_032553.1| Homo sapiens putative purinergic receptor (FKSG79), mRNA
Length = 1258, Score = 2419 bits (1258), Expect = 0.0, Identities = 1258/1258 (100%)
- >dbj|AB083599.1| Homo sapiens GPCR gene for putative G-protein coupled receptor, complete
20 CDS, clone:hGPCR17
Length = 1002, Score = 1927 bits (1002), Expect = 0.0, Identities = 1002/1002 (100%)
- >emb|AL663081.10| Mouse DNA sequence from clone RP23-138F13 on chromosome X, complete
sequence
Length = 206915, Score = 1183 bits (615), Expect = 0.0, Identities = 866/989 (87%), Gaps = 1/989
25 (0%)
- >emb|Z82200.1|HS333E23 Human DNA sequence from clone RP3-333E23 on chromosome
Xq21.1, complete sequence
Length = 128011, Score = 64.1 bits (33), Expect = 5e-07, Identities = 57/69 (82%)
- >gb|AF000545.1|HSAF000545 Homo sapiens putative purinergic receptor P2Y10 gene, complete
30 cds

- 80 -

- Length = 1020, Score = 64.1 bits (33), Expect = 5e-07, Identities = 57/69 (82%)
- >ref|NM_198333.1| Homo sapiens purinergic receptor P2Y, G-protein coupled, 10 (P2RY10), transcript variant 2, mRNA
- Length = 1679, Score = 64.1 bits (33), Expect = 5e-07, Identities = 57/69 (82%)
- 5 >ref|NM_014499.2| Homo sapiens purinergic receptor P2Y, G-protein coupled, 10 (P2RY10), transcript variant 1, mRNA
- Length = 1871, Score = 64.1 bits (33), Expect = 5e-07, Identities = 57/69 (82%)
- >dbj|AK020001.1| Mus musculus adult male thymus cDNA, RIKEN full-length enriched library, clone:5830408N17 product:PUTATIVE PURINERGIC RECEPTOR P2Y10 homolog [Homo sapiens], full insert sequence
- 10 Length = 2706, Score = 52.6 bits (27), Expect = 0.001, Identities = 41/48 (85%)
- >dbj|AK088234.1| Mus musculus 2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430007L23 product:PUTATIVE PURINERGIC RECEPTOR P2Y10 homolog [Homo sapiens], full insert sequence
- 15 Length = 2828, Score = 52.6 bits (27), Expect = 0.001, Identities = 41/48 (85%)
- >dbj|AK041740.1| Mus musculus 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630033H20 product:similar to PUTATIVE PURINERGIC RECEPTOR P2Y10, full insert sequence
- Length = 2066, Score = 52.6 bits (27), Expect = 0.001, Identities = 41/48 (85%)
- 20 >dbj|AK041351.1| Mus musculus 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630004K17 product:PUTATIVE PURINERGIC RECEPTOR P2Y10 homolog [Homo sapiens], full insert sequence
- Length = 2335, Score = 52.6 bits (27), Expect = 0.001, Identities = 41/48 (85%).

Example 2: Expression profiling

- 25 Total cellular RNA was isolated from cells by one of two standard methods: 1) guanidine isothiocyanate/Cesium chloride density gradient centrifugation [Kellogg, (1990)]; or with the Tri-Reagent protocol according to the manufacturer's specifications (Molecular Research Center, Inc., Cincinnati, Ohio). Total RNA prepared by the Tri-reagent protocol was treated with DNase I to remove genomic DNA contamination.
- 30 For relative quantitation of the mRNA distribution of FKSG79, total RNA from each cell or tissue source was first reverse transcribed. 85 µg of total RNA was reverse transcribed using 1 µmole

random hexamer primers, 0.5 mM each of dATP, dCTP, dGTP and dTTP (Qiagen, Hilden, Germany), 3000 U RnaseQut (Invitrogen, Groningen, Netherlands) in a final volume of 680 μ l. The first strand synthesis buffer and Omniscript reverse transcriptase (2 u/ μ l) were from (Qiagen, Hilden, Germany). The reaction was incubated at 37°C for 90 minutes and cooled on ice. The
5 volume was adjusted to 6800 μ l with water, yielding a final concentration of 12.5 ng/ μ l of starting RNA.

For relative quantitation of the distribution of FKSG79 mRNA in cells and tissues the Applied Biosystems 7900 HT Sequence Detection system or Biorad iCycler was used according to the manufacturer's specifications and protocols. PCR reactions were set up to quantitate FKSG79 and
10 the housekeeping genes HPRT (hypoxanthine phosphoribosyltransferase), GAPDH (glyceraldehyde-3-phosphate dehydrogenase), β -actin, and others. Forward and reverse primers and probes for FKSG79 were designed using the Perkin Elmer ABI Primer ExpressTM software and were synthesized by TibMolBiol (Berlin, Germany). The FKSG79 forward primer sequence was: Primer1 (SEQ ID NO: 3). The FKSG79 reverse primer sequence was Primer2 (SEQ ID NO: 4).
15 Probe1 (SEQ ID NO: 5), labelled with FAM (carboxyfluorescein succinimidyl ester) as the reporter dye and TAMRA (carboxytetramethylrhodamine) as the quencher, is used as a probe for FKSG79. The following reagents were prepared in a total of 25 μ l : 1x TaqMan buffer A, 5.5 mM MgCl₂, 200 nM of dATP, dCTP, dGTP, and dUTP, 0.025 U/ μ l AmpliTaq GoldTM, 0.01 U/ μ l AmpErase and Probe1 (SEQ ID NO: 5), FKSG79 forward and reverse primers each at 200 nM,
20 200 nM FKSG79 FAM/TAMRA-labelled probe, and 5 μ l of template cDNA. Thermal cycling parameters were 2 min at 50°C, followed by 10 min at 95°C, followed by 40 cycles of melting at 95°C for 15 sec and annealing/extending at 60°C for 1 min.

Calculation of corrected CT values

The CT (threshold cycle) value is calculated as described in the "Quantitative determination of
25 nucleic acids" section. The CF-value (factor for threshold cycle correction) is calculated as follows :

1. PCR reactions were set up to quantitate the housekeeping genes (HKG) for each cDNA sample.
2. CT_{HKG}-values (threshold cycle for housekeeping gene) were calculated as described in the
30 "Quantitative determination of nucleic acids" section.
3. CT_{HKG}-mean values (CT mean value of all HKG tested on one cDNAs) of all HKG for each cDNA are calculated (n = number of HKG):

$$CT_{\text{HKG-n}}\text{-mean value} = (CT_{\text{HKG1}}\text{-value} + CT_{\text{HKG2}}\text{-value} + \dots + CT_{\text{HKG-n}}\text{-value}) / n$$

$$4. \quad CT_{\text{panel}} \text{ mean value (CT mean value of all HKG in all tested cDNAs)} =$$

$$(CT_{\text{HKG1}}\text{-mean value} + CT_{\text{HKG2}}\text{-mean value} + \dots + CT_{\text{HKG-y}}\text{-mean value}) / y$$

(y = number of cDNAs)

$$5. \quad CF_{\text{cDNA-n}} \text{ (correction factor for cDNA n)} = CT_{\text{panel}}\text{-mean value} - CT_{\text{HKG-n}}\text{-mean value}$$

$$6. \quad CT_{\text{cDNA-n}} \text{ (CT value of the tested gene for the cDNA n)} + CF_{\text{cDNA-n}} \text{ (correction factor for cDNA n)} = CT_{\text{cor-cDNA-n}} \text{ (corrected CT value for a gene on cDNA n)}$$

Calculation of relative expression

Definition : highest $CT_{\text{cor-cDNA-n}} \neq 40$ is defined as $CT_{\text{cor-cDNA}} [\text{high}]$

$$10 \quad \text{Relative Expression} = 2^{(CT_{\text{cor-cDNA}}[\text{high}] - CT_{\text{cor-cDNA-n}})}$$

Tissues

The expression of FKSG79 was investigated in the tissues listed in table 1.

Expression profile

The results of the the mRNA-quantification (expression profiling) is shown in Table 1.

15 *Table 1: Relative expression of FKSG79 in various human tissues.*

T-cells peripheral blood CD4+	9947
T-cells peripheral blood CD4+	3848
T-cells peripheral blood CD4+ D117 II virus infected	5873
T-cells peripheral blood CD4+ D34 virus infected	5330
monocytes	0
monocytes HIV-1 infected	33
fetal heart	0
heart	355
heart	891
heart	5
heart	491

heart myocardial infarction	1090
heart myocardial infarction	47
heart myocardial infarction	0
pericardium	3822
heart atrium (right)	704
heart atrium (right)	50
heart atrium (left)	989
heart atrium (left)	66
heart ventricle (left)	49
heart ventricle (left)	11
heart ventricle (right)	6
heart ventricle (right)	296
heart apex	67
Purkinje fibers	218
interventricular septum	276
fetal aorta	231
aorta	30
aorta	1618
aorta	298
arcus aorta	2320
aorta valve	377
artery	198
coronary artery	246
coronary artery	94
pulmonary artery	163
carotid artery	44
mesenteric artery	45
arteria radialis	20
vein	644
pulmonic valve	867
vein (saphena magna)	246
(caval) vein	1
coronary artery endothel cells	272
coronary artery smooth muscle primary cells	118
aortic smooth muscle cells	0
pulmonary artery smooth muscle cells	26

aortic endothel cells	74
HUVEC cells	31
pulmonary artery endothel cells	0
iliac artery endothel cells	84
skin	1243
adrenal gland	162
thyroid	391
thyroid tumor	294
pancreas	66
pancreas liver cirrhosis	89
esophagus	247
esophagus tumor	2195
stomach	4068
stomach tumor	3304
colon	1152
colon tumor	2195
small intestine	4153
ileum	2778
ileum tumor	4360
ileum chronic inflammation	617
rectum	8079
rectum tumor	184
fetal liver	352
liver	1380
liver	3
liver	8
liver liver cirrhosis	4973
liver lupus disease	28
liver tumor	2628
HEP G2 cells	94
leukocytes (peripheral blood)	10809
Jurkat (T-cells)	46341

Raji (B-cells)	440
bone marrow	1596
erythrocytes	695
lymphnode	3148
thymus	17560
thrombocytes	820
bone marrow stromal cells	910
bone marrow CD71+ cells	110
bone marrow CD33+ cells	613
bone marrow CD34+ cells	516
bone marrow CD15+ cells	152
cord blood CD71+ cells	181
cord blood CD34+ cells	1053
neutrophils cord blood	613
T-cells peripheral blood CD8+	16384
monocytes peripheral blood CD14+	4182
B-cells peripheral blood CD19+	28526
neutrophils peripheral blood	1136
spleen	24492
spleen liver cirrhosis	481
skeletal muscle	107
cartilage	2369
bone connective tissue	370
adipose	111
adipose	1097
adipose	537
fetal adipose	11113
adipose (subcutaneous) BMI 21.74	0
adipose (subcutaneous) BMI 35.04	0
brain	175
cerebellum	7
cerebral cortex	307
frontal lobe	114
occipital lobe	699

parietal lobe	74
temporal lobe	144
substantia nigra	309
caudatum	405
corpus callosum	185
nucleus accumbens	5
putamen	3
hippocampus	422
thalamus	155
posteroventral thalamus	48
dorsalmedial thalamus	98
hypothalamus	1184
dorsal root ganglia	5
spinal cord	320
spinal cord (ventral horn)	172
spinal cord (dorsal horn)	67
glial tumor H4 cells	131
astrocytes	39
retina	228
fetal lung	879
fetal lung fibroblast IMR-90 cells	146
fetal lung fibroblast MRC-5 cells	5
lung	72
lung	588
lung	18
lung right upper lobe	309
lung right mid lobe	501
lung right lower lobe	534
lung lupus disease	171
lung tumor	996
lung COPD	187
trachea	2320
primary bronchia	252
secondary bronchia	161
bronchial epithelial cells	131

bronchial smooth muscle cells	34
small airway epithelial cells	104
cervix	86
testis	52
HeLa cells (cervix tumor)	0
placenta	704
uterus	809
uterus tumor	5008
ovary	50
ovary tumor	1965
breast	1067
breast tumor	10156
mammary gland	1629
prostate	653
prostate	592
prostate	1687
prostate BPH	104
prostate tumor	129
bladder	861
bladder	2180
bladder	1193
ureter	407
penis	137
corpus cavernosum	755
fetal kidney	362
kidney	345
kidney	0
kidney	294
kidney tumor	2226
renal epithelial cells	545
HEK 293 cells	452

Example 3: Antisense Analysis

Knowledge of the correct, complete cDNA sequence coding for FKSG79 enables its use as a tool for antisense technology in the investigation of gene function. Oligonucleotides, cDNA or genomic fragments comprising the antisense strand of a polynucleotide coding for FKSG79 are used either in vitro or in vivo to inhibit translation of the mRNA. Such technology is now well known in the art, and antisense molecules can be designed at various locations along the nucleotide sequences. By treatment of cells or whole test animals with such antisense sequences, the gene of interest is effectively turned off. Frequently, the function of the gene is ascertained by observing behavior at the intracellular, cellular, tissue or organismal level (e.g., lethality, loss of differentiated function, changes in morphology, etc.).

In addition to using sequences constructed to interrupt transcription of a particular open reading frame, modifications of gene expression is obtained by designing antisense sequences to intron regions, promoter/enhancer elements, or even to trans-acting regulatory genes.

Example 4: Expression of FKSG79

Expression of FKSG79 is accomplished by subcloning the cDNAs into appropriate expression vectors and transfecting the vectors into expression hosts such as, e.g., *E. coli*. In a particular case, the vector is engineered such that it contains a promoter for β -galactosidase, upstream of the cloning site, followed by sequence containing the amino-terminal Methionine and the subsequent seven residues of β -galactosidase. Immediately following these eight residues is an engineered bacteriophage promoter useful for artificial priming and transcription and for providing a number of unique endonuclease restriction sites for cloning.

Induction of the isolated, transfected bacterial strain with Isopropyl- β -D-thiogalactopyranoside (IPTG) using standard methods produces a fusion protein corresponding to the first seven residues of β -galactosidase, about 15 residues of "linker", and the peptide encoded within the cDNA. Since cDNA clone inserts are generated by an essentially random process, there is probability of 33% that the included cDNA will lie in the correct reading frame for proper translation. If the cDNA is not in the proper reading frame, it is obtained by deletion or insertion of the appropriate number of bases using well known methods including in vitro mutagenesis, digestion with exonuclease III or mung bean nuclease, or the inclusion of an oligonucleotide linker of appropriate length.

The FKSG79 cDNA is shuttled into other vectors known to be useful for expression of proteins in specific hosts. Oligonucleotide primers containing cloning sites as well as a segment of DNA (about 25 bases) sufficient to hybridize to stretches at both ends of the target cDNA is synthesized

chemically by standard methods. These primers are then used to amplify the desired gene segment by PCR. The resulting gene segment is digested with appropriate restriction enzymes under standard conditions and isolated by gel electrophoresis. Alternately, similar gene segments are produced by digestion of the cDNA with appropriate restriction enzymes. Using appropriate primers, segments of coding sequence from more than one gene are ligated together and cloned in appropriate vectors. It is possible to optimize expression by construction of such chimeric sequences.

Suitable expression hosts for such chimeric molecules include, but are not limited to, mammalian cells such as Chinese Hamster Ovary (CHO) and human 293 cells., insect cells such as Sf9 cells, yeast cells such as *Saccharomyces cerevisiae* and bacterial cells such as *E. coli*. For each of these cell systems, a useful expression vector also includes an origin of replication to allow propagation in bacteria, and a selectable marker such as the β -lactamase antibiotic resistance gene to allow plasmid selection in bacteria. In addition, the vector may include a second selectable marker such as the neomycin phosphotransferase gene to allow selection in transfected eukaryotic host cells. Vectors for use in eukaryotic expression hosts require RNA processing elements such as 3' polyadenylation sequences if such are not part of the cDNA of interest.

Additionally, the vector contains promoters or enhancers which increase gene expression. Such promoters are host specific and include MMTV, SV40, and metallothionine promoters for CHO cells; trp, lac, tac and T7 promoters for bacterial hosts; and alpha factor, alcohol oxidase and PGH promoters for yeast. Transcription enhancers, such as the rous sarcoma virus enhancer, are used in mammalian host cells. Once homogeneous cultures of recombinant cells are obtained through standard culture methods, large quantities of recombinantly produced FKSG79 are recovered from the conditioned medium and analyzed using chromatographic methods known in the art. For example, FKSG79 can be cloned into the expression vector pcDNA3, as exemplified herein. This product can be used to transform, for example, HEK293 or COS by methodology standard in the art. Specifically, for example, using Lipofectamine (Gibco BRL catalog no. 18324-020) mediated gene transfer.

Example 5: Isolation of Recombinant FKSG79

FKSG79 is expressed as a chimeric protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals [Appa Rao, 1997] and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Washington). The inclusion of a cleavable linker

sequence such as Factor Xa or enterokinase (Invitrogen, Groningen, The Netherlands) between the purification domain and the FKSG79 sequence is useful to facilitate expression of FKSG79.

Example 6: Testing of Chimeric GPCRs

5 Functional chimeric GPCRs are constructed by combining the extracellular receptive sequences of a new isoform with the transmembrane and intracellular segments of a known isoform for test purposes. This concept was demonstrated by Kobilka et al. (1988), Science 240:1310-1316) who created a series of chimeric $\alpha 2$ - $\beta 2$ adrenergic receptors (AR) by inserting progressively greater amounts of $\alpha 2$ -AR transmembrane sequence into $\beta 2$ -AR. The binding activity of known agonists changed as the molecule shifted from having more $\alpha 2$ than $\beta 2$ conformation, and intermediate
10 constructs demonstrated mixed specificity. The specificity for binding antagonists, however, correlated with the source of the domain VII. The importance of T7G domain VII for ligand recognition was also found in chimeras utilizing two yeast α -factor receptors and is significant because the yeast receptors are classified as miscellaneous receptors. Thus, functional role of specific domains appears to be preserved throughout the GPCR family regardless of category.

15 In parallel fashion, internal segments or cytoplasmic domains from a particular isoform are exchanged with the analogous domains of a known GPCRs and used to identify the structural determinants responsible for coupling the receptors to trimeric G-proteins. A chimeric receptor in which domains V, VI, and the intracellular connecting loop from $\beta 2$ -AR were substituted into $\alpha 2$ -AR was shown to bind ligands with $\alpha 2$ -AR specificity, but to stimulate adenylate cyclase in the
20 manner of $\beta 2$ -AR. This demonstrates that for adrenergic-type receptors, G-protein recognition is present in domains V and VI and their connecting loop. The opposite situation was predicted and observed for a chimera in which the V->VI loop from $\alpha 1$ -AR replaced the corresponding domain on $\beta 2$ -AR and the resulting receptor bound ligands with $\beta 2$ -AR specificity and activated G-protein-mediated phosphatidylinositol turnover in the $\alpha 1$ -AR manner. Finally, chimeras constructed from
25 muscarinic receptors also demonstrated that V->VI loop is the major determinant for specificity of G-protein activity.

Chimeric or modified GPCRs containing substitutions in the extracellular and transmembrane regions have shown that these portions of the receptor determine ligand binding specificity. For example, two Serine residues conserved in domain V of all adrenergic and D catecholamine
30 GPCRs are necessary for potent agonist activity. These serines are believed to form hydrogen bonds with the catechol moiety of the agonists within the GPCR binding site. Similarly, an Asp residue present in domain III of all GPCRs which bind biogenic amines is believed to form an ion pair with the ligand amine group in the GPCR binding site.

Functional, cloned GPCRs are expressed in heterologous expression systems and their biological activity assessed. One heterologous system introduces genes for a mammalian GPCR and a mammalian G-protein into yeast cells. The GPCR is shown to have appropriate ligand specificity and affinity and trigger appropriate biological activation (growth arrest and morphological changes) of the yeast cells.

An alternate procedure for testing chimeric receptors is based on the procedure utilizing the purinergic receptor (P_{2u}). Function is easily tested in cultured K562 human leukemia cells because these cells lack P_{2u} receptors. K562 cells are transfected with expression vectors containing either normal or chimeric P_{2u} and loaded with fura-a, fluorescent probe for Ca^{++} . Activation of properly assembled and functional P_{2u} receptors with extracellular UTP or ATP mobilizes intracellular Ca^{++} which reacts with fura-a and is measured spectrofluorometrically.

As with the GPCRs above, chimeric genes are created by combining sequences for extracellular receptive segments of any new GPCR polypeptide with the nucleotides for the transmembrane and intracellular segments of the known P_{2u} molecule. Bathing the transfected K562 cells in microwells containing appropriate ligands triggers binding and fluorescent activity defining effectors of the GPCR molecule. Once ligand and function are established, the P_{2u} system is useful for defining antagonists or inhibitors which block binding and prevent such fluorescent reactions.

Example 7: Production of FKSG79 Specific Antibodies

Two approaches are utilized to raise antibodies to FKSG79, and each approach is useful for generating either polyclonal or monoclonal antibodies. In one approach, denatured protein from reverse phase HPLC separation is obtained in quantities up to 75 mg. This denatured protein is used to immunize mice or rabbits using standard protocols; about 100 μ g are adequate for immunization of a mouse, while up to 1 mg might be used to immunize a rabbit. For identifying mouse hybridomas, the denatured protein is radioiodinated and used to screen potential murine B-cell hybridomas for those which produce antibody. This procedure requires only small quantities of protein, such that 20 mg is sufficient for labeling and screening of several thousand clones.

In the second approach, the amino acid sequence of an appropriate FKSG79 domain, as deduced from translation of the cDNA, is analyzed to determine regions of high antigenicity. Oligopeptides comprising appropriate hydrophilic regions are synthesized and used in suitable immunization protocols to raise antibodies. The optimal amino acid sequences for immunization are usually at the C-terminus, the N-terminus and those intervening, hydrophilic regions of the polypeptide

which are likely to be exposed to the external environment when the protein is in its natural conformation.

Typically, selected peptides, about 15 residues in length, are synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry and coupled to keyhole limpet hemocyanin (KLH; Sigma, St. Louis, MO) by reaction with M-maleimidobenzoyl-N-hydroxy-succinimide ester, MBS. If necessary, a cysteine is introduced at the N-terminus of the peptide to permit coupling to KLH. Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for anti-peptide activity by binding the peptide to plastic, blocking with 1% bovine serum albumin, reacting with antisera, washing and reacting with labeled (radioactive or fluorescent), affinity purified, specific goat anti-rabbit IgG.

Hybridomas are prepared and screened using standard techniques. Hybridomas of interest are detected by screening with labeled FKSG79 to identify those fusions producing the monoclonal antibody with the desired specificity. In a typical protocol, wells of plates (FAST; Becton-Dickinson, Palo Alto, CA) are coated during incubation with affinity purified, specific rabbit anti-mouse (or suitable antispecies 1 g) antibodies at 10 mg/ml. The coated wells are blocked with 1% bovine serum albumin, (BSA), washed and incubated with supernatants from hybridomas. After washing the wells are incubated with labeled FKSG79 at 1 mg/ml. Supernatants with specific antibodies bind more labeled FKSG79 than is detectable in the background. Then clones producing specific antibodies are expanded and subjected to two cycles of cloning at limiting dilution. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from mouse ascitic fluid by affinity chromatography on Protein A. Monoclonal antibodies with affinities of at least

10^8 M^{-1} , preferably 10^9 to 10^{10} M^{-1} or stronger, are typically made by standard procedures.

Example 8: Diagnostic Test Using FKSG79 Specific Antibodies

Particular FKSG79 antibodies are useful for investigating signal transduction and the diagnosis of infectious or hereditary conditions which are characterized by differences in the amount or distribution of FKSG79 or downstream products of an active signaling cascade.

Diagnostic tests for FKSG79 include methods utilizing antibody and a label to detect FKSG79 in human body fluids, membranes, cells, tissues or extracts of such. The polypeptides and antibodies of the present invention are used with or without modification. Frequently, the polypeptides and antibodies are labeled by joining them, either covalently or noncovalently, with a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known

and have been reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent agents, chromogenic agents, magnetic particles and the like.

5 A variety of protocols for measuring soluble or membrane-bound FKSG79, using either polyclonal or monoclonal antibodies specific for the protein, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on FKSG79 is preferred, but a competitive binding assay may be employed.

10 **Example 9: Purification of Native FKSG79 Using Specific Antibodies**

Native or recombinant FKSG79 is purified by immunoaffinity chromatography using antibodies specific for FKSG79. In general, an immunoaffinity column is constructed by covalently coupling the anti-TRH antibody to an activated chromatographic resin.

15 Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway N.J.). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated Sepharose (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is
20 blocked, and the derivative resin is washed according to the manufacturer's instructions.

Such immunoaffinity columns are utilized in the purification of FKSG79 by preparing a fraction from cells containing FKSG79 in a soluble form. This preparation is derived by solubilization of whole cells or of a subcellular fraction obtained via differential centrifugation (with or without addition of detergent) or by other methods well known in the art. Alternatively, soluble FKSG79
25 containing a signal sequence is secreted in useful quantity into the medium in which the cells are grown.

A soluble FKSG79-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of FKSG79 (e.g., high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions
30 that disrupt antibody/protein binding (e.g., a buffer of pH 2-3 or a high concentration of a chaotrope such as urea or thiocyanate ion), and FKSG79 is collected.

Example 10: Drug Screening

This invention is particularly useful for screening therapeutic compounds by using FKSG79 or binding fragments thereof in any of a variety of drug screening techniques. As FKSG79 is a G protein coupled receptor any of the methods commonly used in the art may potentially be used to identify FKSG79 ligands. For example, the activity of a G protein coupled receptor such as FKSG79 can be measured using any of a variety of appropriate functional assays in which activation of the receptor results in an observable change in the level of some second messenger system, such as adenylate cyclase, guanylylcyclase, calcium mobilization, or inositol phospholipid hydrolysis. Alternatively, the polypeptide or fragment employed in such a test is either free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, are used for standard binding assays.

Measured, for example, is the formation of complexes between FKSG79 and the agent being tested. Alternatively, one examines the diminution in complex formation between FKSG79 and a ligand caused by the agent being tested.

Thus, the present invention provides methods of screening for drug candidates, drugs, or any other agents which affect signal transduction. These methods, well known in the art, comprise contacting such an agent with FKSG79 polypeptide or a fragment thereof and assaying (i) for the presence of a complex between the agent and FKSG79 polypeptide or fragment, or (ii) for the presence of a complex between FKSG79 polypeptide or fragment and the cell. In such competitive binding assays, the FKSG79 polypeptide or fragment is typically labeled. After suitable incubation, free FKSG79 polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to FKSG79 or to interfere with the FKSG79-agent complex.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to FKSG79 polypeptides. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with FKSG79 polypeptide and washed. Bound FKSG79 polypeptide is then detected by methods well known in the art. Purified FKSG79 are also coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies are used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding FKSG79 specifically compete with a test compound for binding to FKSG79 polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic determinants with FKSG79.

5 **Example 11: Rational Drug Design**

The goal of rational drug design is to produce structural analogs of biologically active polypeptides of interest or of small molecules with which they interact, agonists, antagonists, or inhibitors. Any of these examples are used to fashion drugs which are more active or stable forms of the polypeptide or which enhance or interfere with the function of a polypeptide in vivo.

10 In one approach, the three-dimensional structure of a protein of interest, or of a protein-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the polypeptide must be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful information regarding the structure of a polypeptide is gained by modeling based on the
15 structure of homologous proteins. In both cases, relevant structural information is used to design efficient inhibitors. Useful examples of rational drug design include molecules which have improved activity or stability or which act as inhibitors, agonists, or antagonists of native peptides.

It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore
20 upon which subsequent drug design is based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids is expected to be an analog of the original receptor. The anti-id is then used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides then act as the
25 pharmacore.

By virtue of the present invention, sufficient amount of polypeptide are made available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the FKSG79 amino acid sequence provided herein provides guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.

30 **Example 12: Identification of Other Members of the Signal Transduction Complex**

The inventive purified FKSG79 is a research tool for identification, characterization and purification of interacting G or other signal transduction pathway proteins. Radioactive labels are

incorporated into a selected FKSG79 domain by various methods known in the art and used in vitro to capture interacting molecules. A preferred method involves labeling the primary amino groups in FKSG79 with ¹²⁵I Bolton-Hunter reagent. This reagent has been used to label various molecules without concomitant loss of biological activity.

5 Labeled FKSG79 is useful as a reagent for the purification of molecules with which it interacts. In one embodiment of affinity purification, membrane-bound FKSG79 is covalently coupled to a chromatography column. Cell-free extract derived from synovial cells or putative target cells is passed over the column, and molecules with appropriate affinity bind to FKSG79. FKSG79-
10 complex is recovered from the column, and the FKSG79-binding ligand disassociated and subjected to N-terminal protein sequencing. The amino acid sequence information is then used to identify the captured molecule or to design degenerate oligonucleotide probes for cloning the relevant gene from an appropriate cDNA library.

In an alternate method, antibodies are raised against FKSG79, specifically monoclonal antibodies. The monoclonal antibodies are screened to identify those which inhibit the binding of labeled
15 FKSG79. These monoclonal antibodies are then used therapeutically.

Example 13: Use and Administration of Antibodies, Inhibitors, or Antagonists

Antibodies, inhibitors, or antagonists of FKSG79 or other treatments and compounds that are limiters of signal transduction (LSTs), provide different effects when administered therapeutically. LSTs are formulated in a nontoxic, inert, pharmaceutically acceptable aqueous carrier medium
20 preferably at a pH of about 5 to 8, more preferably 6 to 8, although pH may vary according to the characteristics of the antibody, inhibitor, or antagonist being formulated and the condition to be treated. Characteristics of LSTs include solubility of the molecule, its half-life and antigenicity/immunogenicity. These and other characteristics aid in defining an effective carrier. Native human proteins are preferred as LSTs, but organic or synthetic molecules resulting from
25 drug screens are equally effective in particular situations.

LSTs are delivered by known routes of administration including but not limited to topical creams and gels; transmucosal spray and aerosol; transdermal patch and bandage; injectable, intravenous and lavage formulations; and orally administered liquids and pills particularly formulated to resist stomach acid and enzymes. The particular formulation, exact dosage, and route of administration
30 is determined by the attending physician and varies according to each specific situation.

Such determinations are made by considering multiple variables such as the condition to be treated, the LST to be administered, and the pharmacokinetic profile of a particular LST.

Additional factors which are taken into account include severity of the disease state, patient's age, weight, gender and diet, time and frequency of LST administration, possible combination with other drugs, reaction sensitivities, and tolerance/response to therapy. Long acting LST formulations might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular LST.

Normal dosage amounts vary from 0.1 to 10^5 μg , up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see U.S. Pat. Nos. 4,657,760; 5,206,344; or 5,225,212. Those skilled in the art employ different formulations for different LSTs. Administration to cells such as nerve cells necessitates delivery in a manner different from that to other cells such as vascular endothelial cells.

It is contemplated that abnormal signal transduction, trauma, or diseases which trigger FKSG79 activity are treatable with LSTs. These conditions or diseases are specifically diagnosed by the tests discussed above, and such testing should be performed in suspected cases of viral, bacterial or fungal infections, allergic responses, mechanical injury associated with trauma, hereditary diseases, lymphoma or carcinoma, or other conditions which activate the genes of lymphoid or neuronal tissues.

Example 14: Production of Non-human Transgenic Animals

Animal model systems which elucidate the physiological and behavioral roles of the FKSG79 are produced by creating nonhuman transgenic animals in which the activity of the FKSG79 is either increased or decreased, or the amino acid sequence of the expressed FKSG79 is altered, by a variety of techniques. Examples of these techniques include, but are not limited to: 1) Insertion of normal or mutant versions of DNA encoding a FKSG79, by microinjection, electroporation, retroviral transfection or other means well known to those skilled in the art, into appropriately fertilized embryos in order to produce a transgenic animal or 2) homologous recombination of mutant or normal, human or animal versions of these genes with the native gene locus in transgenic animals to alter the regulation of expression or the structure of these FKSG79 sequences. The technique of homologous recombination is well known in the art. It replaces the native gene with the inserted gene and hence is useful for producing an animal that cannot express native FKSG79s but does express, for example, an inserted mutant FKSG79, which has replaced the native FKSG79 in the animal's genome by recombination, resulting in underexpression of the transporter. Microinjection adds genes to the genome, but does not remove them, and the technique is useful for producing an animal which expresses its own and added FKSG79, resulting in overexpression of the FKSG79.

One means available for producing a transgenic animal, with a mouse as an example, is as follows: Female mice are mated, and the resulting fertilized eggs are dissected out of their oviducts. The eggs are stored in an appropriate medium such as cesiumchloride M2 medium. DNA or cDNA encoding FKSG79 is purified from a vector by methods well known to the one skilled in the art.

5 Inducible promoters may be fused with the coding region of the DNA to provide an experimental means to regulate expression of the transgene. Alternatively or in addition, tissue specific regulatory elements may be fused with the coding region to permit tissue-specific expression of the transgene. The DNA, in an appropriately buffered solution, is put into a microinjection needle (which may be made from capillary tubing using a piper puller) and the egg to be injected is put in

10 a depression slide. The needle is inserted into the pronucleus of the egg, and the DNA solution is injected. The injected egg is then transferred into the oviduct of a pseudopregnant mouse which is a mouse stimulated by the appropriate hormones in order to maintain false pregnancy, where it proceeds to the uterus, implants, and develops to term. As noted above, microinjection is not the only method for inserting DNA into the egg but is used here only for exemplary purposes.

15 **References**

- U.S. 4,522,811
U.S. 5,283,317
U.S. 5,565,332
WO 84/03564
20 WO 92/01810
WO 93/03151
WO 94/13804
WO 01/04297
WO 01/98351
25 WO 02/061087
WO 02/068579
Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ; *Nucleic Acids Res* 1997 Sep 1; 25(17): 3389-402
Appa Rao et al., 1997, *Protein Expr Purif* Nov, 11(2): 201-8
30 Barnes, 2000, *Chest*, 117:10S14S
Botstein et al., 1980, *Am J Hum Genet.* 32: 314-31
Colbere-Garapin et al., 1981, *J. Mol. Biol.* 150, 1-14
Engelhard et al., 1994, *Proc. Nat. Acad. Sci.* 91, 3224-3227
Gergen and Weiss, 1992, *Am Rev Respir Dis* 146:823-824
35 Gibson et al., 1996, *Genome Research* 6: 995-1001

- Haseloff *et al.*, 1988 , *Nature* 334, 585-591
- Heid *et al.*, 1996, *Genome Research* 6: 986-994
- Holland *et al.*, 1991, *PNAS* 88: 7276-7280
- Iwabuchi *et al.*, 1993, *Oncogene* 8, 1693-1696
- 5 Jeffreys *et al.*, 1985, *Nature* 316: 76-9
- Johnson *et al.*, 1989, *Endoc. Rev.* 10, 317-331
- Kellogg *et al.*, 1990, *Anal. Biochem.* 189:202-208
- Lam , 1997, *Anticancer Drug Res.* 12(3):145-67
- Lefkowitz, 1991 , *Nature* 351, 353-354
- 10 Livak *et al.*, 1995 , *PCR Methods and Applications* 357-362
- Logan, Shenk, 1984, *Proc. Natl. Acad. Sci.* 81, 3655-3659
- Lowy *et al.*, 1980, *Cell* 22, 817-23
- Maddox *et al.*, 1983, *J. Exp. Med.* 158, 1211-1216
- McConnell *et al.* , 1992 , *Science* 257, 1906-1912
- 15 Mitaku *et al.* (2002), *FEBS Lett.* Jun 5;520(1-3):97-101.
- Nicholls *et al.*, 1993, *J. Immunol. Meth.* 165, 81-91
- Piatak *et al.*, 1993, *BioTechniques* 14:70-81
- Piatak *et al.*, 1993, *Science* 259:1749-1754
- Porath *et al.*, 1992, *Prot. Exp. Purif.* 3, 263-281
- 20 Roberge *et al.*, 1995, *Science* 269, 202-204
- Sjolander, Urbaniczky, 1991, *Anal. Chem.* 63, 2338-2345
- Szabo *et al.*, 1995, *Curr. Opin. Struct. Biol.* 5, 699-705
- Thomas, 1980, *Proc. Nat. Acad. Sci.*, 77:5201-5205
- Uhlmann *et al.*, 1987, *Tetrahedron. Lett.* 215, 3539-3542
- 25 Weber *et al.*, 1990, *Genomics* 7: 524-30
- Wigler *et al.*, 1977, *Cell* 11, 223-32
- Wigler *et al.*, 1980, *Proc. Natl. Acad. Sci.* 77, 3567-70

Claims

1. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising the steps of
 - i) contacting a test compound with a FKSG79 polypeptide,
 - ii) detect binding of said test compound to said FKSG79 polypeptide.
2. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising the steps of
 - i) determining the activity of a FKSG79 polypeptide at a certain concentration of a test compound or in the absence of said test compound,
 - ii) determining the activity of said polypeptide at a different concentration of said test compound.
3. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising the steps of
 - i) determining the activity of a FKSG79 polypeptide at a certain concentration of a test compound,
 - ii) determining the activity of a FKSG79 polypeptide at the presence of a compound known to be a regulator of a FKSG79 polypeptide.
4. The method of any of claims 1 to 3, wherein the step of contacting is in or at the surface of a cell.
5. The method of any of claims 1 to 3, wherein the cell is in vitro.
6. The method of any of claims 1 to 3, wherein the step of contacting is in a cell-free system.

7. The method of any of claims 1 to 3, wherein the polypeptide is coupled to a detectable label.
8. The method of any of claims 1 to 3, wherein the compound is coupled to a detectable label.
9. The method of any of claims 1 to 3, wherein the test compound displaces a ligand which is first bound to the polypeptide.
10. The method of any of claims 1 to 3, wherein the polypeptide is attached to a solid support.
11. The method of any of claims 1 to 3, wherein the compound is attached to a solid support.
12. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising the steps of
 - i) contacting a test compound with a FKSG79 polynucleotide,
 - ii) detect binding of said test compound to said FKSG79 polynucleotide.
13. The method of claim 12 wherein the nucleic acid molecule is RNA.
14. The method of claim 12 wherein the contacting step is in or at the surface of a cell.
15. The method of claim 12 wherein the contacting step is in a cell-free system.
16. The method of claim 12 wherein polynucleotide is coupled to a detectable label.
17. The method of claim 12 wherein the test compound is coupled to a detectable label.
18. A method of diagnosing a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising the steps of
 - i) determining the amount of a FKSG79 polynucleotide in a sample taken from said mammal,
 - ii) determining the amount of FKSG79 polynucleotide in healthy and/or diseased mammals.

19. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising a therapeutic agent which binds to a FKSG79 polypeptide.
20. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising a therapeutic agent which regulates the activity of a FKSG79 polypeptide.
21. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising a therapeutic agent which regulates the activity of a FKSG79 polypeptide, wherein said therapeutic agent is
- i) a small molecule,
 - ii) an RNA molecule,
 - iii) an antisense oligonucleotide,
 - iv) a polypeptide,
 - v) an antibody, or
 - vi) a ribozyme.
22. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising a FKSG79 polynucleotide.
23. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases,

respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising a FKSG79 polypeptide.

24. Use of regulators of a FKSG79 for the preparation of a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal.
25. Method for the preparation of a pharmaceutical composition useful for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal comprising the steps of
- i) identifying a regulator of FKSG79,
 - ii) determining whether said regulator ameliorates the symptoms of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases in a mammal; and
 - iii) combining of said regulator with an acceptable pharmaceutical carrier.
26. Use of a regulator of FKSG79 for the regulation of FKSG79 activity in a mammal having a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases.

Fig. 1**SEQ ID NO: 1**

CACCATTAGGCAAAGATAGTTTCTCTAGAGAGAATCATGCCTGCTAATTACA
CGTGTACCAGGCCAGATGGAGACAATACAGATTTTCGATACTTTATTTATGC
AGTGACATACTGTTCATTCTTGTGCCAGGTCTCATAGGGAATATATTAGCC
CTGTGGGTATTCTATGGTTATATGAAAGAAACAAAACGAGCTGTGATATTTA
TGATAAACTTAGCCATTGCTGACTTACTACAAGTTCTTTCCTTGCCACTGAG
GATCTTCTACTACTTGAATCATGACTGGCCATTTGGGCCTGGTCTCTGCATG
TTCTGTTTCTACCTGAAGTATGTCAACATGTATGCAAGCATCTACTTCTTGG
TCTGCATCAGTGTGCGACGATTTTGGTTTCTCATGTACCCCTTTCGCTTCCA
TGACTGCAAACAGAAATATGACCTGTACATCAGCATTGCTGGCTGGCTGATC
ATCTGCCTTGCCGTGTGACTCTTTCCTCCTCAGAACCAGTGATGATACCT
CTGGCAATAGGACCAAATGCTTTGTGGATCTTCCTACCAGGAATGTCAACCT
GGCCCAGTCCGTTGTTATGATGACCATTGGCGAGTTGATTGGGTTTGTA
ACTCCGCTTCTGATTGTCCTATATTGTACCTGGAAGACGGTTTTATCACTGCAAG
ATAAATATCCCATGGCCCAAGATCTTGGAGAGAAACAGAAAGCCTTGAAGAT
GATTCTAACCTGTGCAGGGGTATTCCTAATTTGCTTTGCACCTTATCATTTT
AGTTTTCTTTAGATTTCTCTGGTGAAGTCCAATGAAATTAAAAGCTGCCTAG
CCAGAAGGGTGATTCTAATAATTTCAATCTGTGGCATTGTGTCTTGCTAGTCT
GAATTCATGTCTTGACCCAGTCATATACTACTTTTCCACTAATGAGTTCCGA
AGACGGCTTTC AAGACAAGATTTGCATGACAGCATCCA ACTCCATGCAAAAT
CCTTTGTGAGTAACCATAACAGCTTCCACCATGACACCTGAATTATGCTAAAA
CAAAAACCAA ACTGAATGTGACCTGAAATGCAAGTACATCAGAACATATCT
GCAATACCCAAGCCACAGGGAAGAACTTGCAAAACAACACAGCTTTTTCAGTT
CTGCTCTATCTTACTGCTATGGGGAATTC ACTTCTTCAAAGCAGGACCTATT
TGGAGCATTACGATCCACGATTATTGATGTTGACATGTCCATGTAGTAATTT
TTCTTCAAGT

Fig. 2**SEQ ID NO: 2**

MPANYTCTRPGDNTDFRYFIYAVTYTVILVPGGLIGNILALWVFGYMKETK
RAVIFMINLAIADLLQVLSLPLRIFYYLNHDWPFPGPLCMFCFYLKYNMYA
SIYFLVCISVRRFWFLMYPFRFHDCKQKYDLYISIAGWLIICLACVLFPLLR
TSDDTSGNRTKCFVDLPTRNVNLAQSVMMTIGELIGFVTPLLIVLYCTWKT
VLSLQDKYPMAQDLGKQKALKMILTCAGVFLICFAPYHFSFPLDFLVKSNE
IKSCLARRVILIFHSVALCLASLNSCLDPVIYYFSTNEFRRRLSRQDLHDSI
QLHAKSFVSNHTASTMTPELC

Fig. 3**SEQ ID NO: 3**

5' -GGATCTTCCTACCAGGAATGTCA-3'

Fig. 4**SEQ ID NO: 4**

5' -CCCAATCAACTCGCCAATG-3'

Fig. 5**SEQ ID NO: 5**

5' -CCTGGCCCAGTCCGTTGTTATGATGA-3'

SEQUENCE LISTING

<110> Bayer HealthCare AG

<120> Diagnostics and Therapeutics for Diseases Associated with Human
G-Protein Coupled Receptor FKSG79 (FKSG79)

<130> BHC 04 01 124

<160> 5

<170> PatentIn version 3.2

<210> 1

<211> 1258

<212> DNA

<213> Homo sapiens

<400> 1

```

caccattagg caaagatagt ttctctagag agaatcatgc ctgctaatta cacgtgtacc      60
aggccagatg gagacaatac agatTTTTga tactttatTT atgcagtgc atacactgtc      120
attcttgtgc caggtctcat agggaatata ttagccctgt gggTattota tggTtatatg      180
aaagaaacaa aacgagctgt gatattttatg ataaacttag ccattgctga cttactacaa      240
gttcttttct tgccactgag gatctttctac tacttgaatc atgactggcc atttgggcct      300
ggctcttgca tgttctgTTT ctacctgaag tatgtcaaca tgtatgcaag catctacttc      360
ttggctcgca tcagtgtgcg acgattttgg tttctcatgt acccctttog cttccatgac      420
tgcaaacaga aatatgacct gtacatcagc attgctggct ggctgatcat ctgccttgcc      480
tgtgtactct ttccactcct cagaaccagt gatgatacct ctggcaatag gaccaaatgc      540
tttTgtggatc ttctaccag gaatgtcaac ctggcccagt ccgttTgttat gatgaccatt      600
ggcgagttga ttgggtttgt aactocgctt ctgattgtcc tatattgtac ctggaagacg      660
gttttatcac tgcaagataa atatcccatg gcccaagatc ttggagagaa acagaaagcc      720
ttgaagatga ttctaacctg tgcaggggta ttctaattt gctttgcacc ttatcatttc      780
agttttctct tagatttctt ggtgaagtcc aatgaaatta aaagctgcct agccagaagg      840
gtgattctaa tatttcattc tgtggcattg tgtcttgcta gtctgaattc atgtcttgac      900
ccagtcatat actacttttc cactaatgag ttccgaagac ggctttcaag acaagatttg      960
catgacagca tccaactoca tgcaaatcc tttgtgagta accatacagc ttccaccatg      1020
acacctgaat tatgctaaaa caaaaaacca aactgaatgt gacctgaaat gcaagtacat      1080
cagaacatat ctgcaatacc caagccacag ggaagaactt gcaaaacaac acagcttttc      1140
agttctgctc tatcttactg ctatggggaa ttcacttctt caaagcagga cctatttgga      1200
gcattacgat ccacgattat tgatgttgac atgtccatgt agtaattttt cttcaagt      1258

```

<210> 2

<211> 333

<212> PRT

<213> Homo sapiens

<400> 2

```

Met Pro Ala Asn Tyr Thr Cys Thr Arg Pro Asp Gly Asp Asn Thr Asp
1           5           10           15
Phe Arg Tyr Phe Ile Tyr Ala Val Thr Tyr Thr Val Ile Leu Val Pro
           20           25           30
Gly Leu Ile Gly Asn Ile Leu Ala Leu Trp Val Phe Tyr Gly Tyr Met
           35           40           45
Lys Glu Thr Lys Arg Ala Val Ile Phe Met Ile Asn Leu Ala Ile Ala
           50           55           60
Asp Leu Leu Gln Val Leu Ser Leu Pro Leu Arg Ile Phe Tyr Tyr Leu
65           70           75           80
Asn His Asp Trp Pro Phe Gly Pro Gly Leu Cys Met Phe Cys Phe Tyr
           85           90           95
Leu Lys Tyr Val Asn Met Tyr Ala Ser Ile Tyr Phe Leu Val Cys Ile
           100          105          110
Ser Val Arg Arg Phe Trp Phe Leu Met Tyr Pro Phe Arg Phe His Asp
           115          120          125
Cys Lys Gln Lys Tyr Asp Leu Tyr Ile Ser Ile Ala Gly Trp Leu Ile
           130          135          140
Ile Cys Leu Ala Cys Val Leu Phe Pro Leu Leu Arg Thr Ser Asp Asp
145          150          155          160
Thr Ser Gly Asn Arg Thr Lys Cys Phe Val Asp Leu Pro Thr Arg Asn
           165          170          175
Val Asn Leu Ala Gln Ser Val Val Met Met Thr Ile Gly Glu Leu Ile
           180          185          190
Gly Phe Val Thr Pro Leu Leu Ile Val Leu Tyr Cys Thr Trp Lys Thr
           195          200          205
Val Leu Ser Leu Gln Asp Lys Tyr Pro Met Ala Gln Asp Leu Gly Glu
           210          215          220
Lys Gln Lys Ala Leu Lys Met Ile Leu Thr Cys Ala Gly Val Phe Leu
225          230          235          240
Ile Cys Phe Ala Pro Tyr His Phe Ser Phe Pro Leu Asp Phe Leu Val
           245          250          255
Lys Ser Asn Glu Ile Lys Ser Cys Leu Ala Arg Arg Val Ile Leu Ile
           260          265          270
Phe His Ser Val Ala Leu Cys Leu Ala Ser Leu Asn Ser Cys Leu Asp
           275          280          285
Pro Val Ile Tyr Tyr Phe Ser Thr Asn Glu Phe Arg Arg Arg Leu Ser
           290          295          300
Arg Gln Asp Leu His Asp Ser Ile Gln Leu His Ala Lys Ser Phe Val
305          310          315          320
Ser Asn His Thr Ala Ser Thr Met Thr Pro Glu Leu Cys
           325          330

```

<210> 3
<211> 23
<212> DNA
<213> artificial sequence

<220>
<223> forward primer

<400> 3
ggatcttcct accaggaatg tca 23

<210> 4
<211> 19
<212> DNA
<213> artificial sequence

<220>
<223> reverse primer

<400> 4
cccaatcaac tcgccaatg 19

<210> 5
<211> 26
<212> DNA
<213> artificial sequence

<220>
<223> probe

<400> 5
cctggcccag tccggttgta tgatga 26

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/003824

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 G01N33/68 C12Q1/68 A61K38/17				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 G01N C12Q A61K				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, Sequence Search, WPI Data, BIOSIS, PAJ				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
A	PATENT ABSTRACTS OF JAPAN vol. 199, no. 814, 31 December 1998 (1998-12-31) -& JP 10 248582 A (ASAHI CHEM IND CO LTD), 22 September 1998 (1998-09-22) abstract; sequences 1-3 -----			
A	WO 02/061087 A (LIFESPAN BIOSCIENCES, INC; BURMER, GLENNA, C; ROUSH, CHRISTINE, L; BRO) 8 August 2002 (2002-08-08) cited in the application page 6 - page 10; sequences 572,573 -----			
A	US 2003/191285 A1 (MIWA MASANORI ET AL) 9 October 2003 (2003-10-09) claims 1-28; figure 9; sequences 1-4 ----- -/--			
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.				
° Special categories of cited documents :				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; border: none; vertical-align: top;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family </td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family			
Date of the actual completion of the international search <div style="text-align: center; font-size: 1.2em;">15 July 2005</div>	Date of mailing of the international search report <div style="text-align: center; font-size: 1.2em;">19 -08- 2005</div>			
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer <div style="text-align: center; font-size: 1.2em;">Schmidt, Harald</div>			

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/003824

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>NEEF M ET AL: "PORTAL HYPERTENSION IS ASSOCIATED WITH INCREASED MRNA LEVELS OF VASOPRESSOR G-PROTEIN-COUPLED RECEPTORS IN HUMAN HEPATIC ARTERIES" EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, BLACKWELL SCIENTIFIC PUBLICATIONS, vol. 33, no. 3, March 2003 (2003-03), pages 249-255, XP008046935 ISSN: 0014-2972 the whole document</p>	
P,X	<p>----- WO 2004/040000 A (PRIMAL, INC; GAITANARIS, GEORGE, A; BERGMANN, JOHN, E; GRAGEROV, ALEXA) 13 May 2004 (2004-05-13) page 254 - page 256; page 79 - page 82; claim 411; table 27; sequences 418,419,979,1270 -----</p>	1-26

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2005/003824

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-26 (all partially)

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-26 (all partially)

Diagnostics, therapeutics and methods of screening for therapeutics relating to diseases associated with FKSG79, wherein the diseases are cardiovascular diseases

2. claims: 1-26 (all partially)

Diagnostics, therapeutics and methods of screening for therapeutics relating to diseases associated with FKSG79, wherein the diseases are infections

3. claims: 1-26 (all partially)

Diagnostics, therapeutics and methods of screening for therapeutics relating to diseases associated with FKSG79, wherein the diseases are dermatological diseases

4. claims: 1-26 (all partially)

Diagnostics, therapeutics and methods of screening for therapeutics relating to diseases associated with FKSG79, wherein the diseases are gastroenterological diseases

5. claims: 1-26 (all partially)

Diagnostics, therapeutics and methods of screening for therapeutics relating to diseases associated with FKSG79, wherein the diseases are cancer

6. claims: 1-26 (all partially)

Diagnostics, therapeutics and methods of screening for therapeutics relating to diseases associated with FKSG79, wherein the diseases are inflammation

7. claims: 1-26 (all partially)

Diagnostics, therapeutics and methods of screening for therapeutics relating to diseases associated with FKSG79, wherein the diseases are metabolic diseases

8. claims: 1-26 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Diagnostics, therapeutics and methods of screening for therapeutics relating to diseases associated with FKSG79, wherein the diseases are hematological diseases

9. claims: 1-26 (all partially)

Diagnostics, therapeutics and methods of screening for therapeutics relating to diseases associated with FKSG79, wherein the diseases are respiratory diseases

10. claims: 1-26 (all partially)

Diagnostics, therapeutics and methods of screening for therapeutics relating to diseases associated with FKSG79, wherein the diseases are muscle skeleton diseases

11. claims: 1-26 (all partially)

Diagnostics, therapeutics and methods of screening for therapeutics relating to diseases associated with FKSG79, wherein the diseases are neurological diseases

12. claims: 1-26 (all partially)

Diagnostics, therapeutics and methods of screening for therapeutics relating to diseases associated with FKSG79, wherein the diseases are urological diseases

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2005/003824

Patent document cited in search report	A	Publication date	Patent family member(s)	Publication date
JP 10248582	A	22-09-1998	NONE	
WO 02061087	A	08-08-2002	US 2003113798 A1 WO 02061087 A2	19-06-2003 08-08-2002
US 2003191285	A1	09-10-2003	AU 3223701 A WO 0159106 A1 JP 2001292784 A	20-08-2001 16-08-2001 23-10-2001
WO 2004040000	A	13-05-2004	AU 2003300776 A1 CA 2498264 A1 WO 2004040000 A2	25-05-2004 13-05-2004 13-05-2004